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What gets measured gets managed. 
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 ABSTRACT 
Acute kidney injury (AKI) is a common and potentially fatal complication in critically 
ill patients. The diagnosis relies on functional markers of decreased glomerular 
filtration rate (GFR) such as creatinine. Unfortunately, a rise in plasma creatinine lags 
behind the early structural changes that occur in response to various renal insults. 
Future treatment of AKI will most certainly be based on early biomarkers of structural 
damage. In addition, better real-time measures of GFR are needed to be able to monitor 
the course of the disease. Cystatin C outperforms creatinine as a marker of GFR in 
stable patients and human neutrophil lipocalin/neutrophil gelatinase-associated 
lipocalin (HNL/NGAL) has emerged as an early biomarker of AKI since it is readily 
synthesized by tubular cells following kidney damage. However, HNL/NGAL is also 
released by neutrophils in response to bacterial infections. Consequently, sepsis may 
affect HNL/NGAL concentrations in plasma and urine. 
 
The aim of this thesis was to investigate the ability of HNL/NGAL and cystatin C to 
predict AKI and/or mortality in critically ill patients as well as to assess the impact of 
sepsis on HNL/NGAL and cystatin C levels in plasma and urine. In addition, we 
wanted to study the ability of two enzyme-linked immunosorbent assays (ELISAs) to 
detect HNL/NGAL released in urine from kidney epithelial cells and neutrophils, 
respectively, during the development of AKI.  
 
Cystatin C predicted long-term mortality independently of AKI severity. Even in 
patients without AKI, elevated cystatin C was associated with increased mortality. 
During the first week in the intensive care unit cystatin C gradually increased, in 
patients both with and without AKI. This increase was similar in septic and non-septic 
patients. Cystatin C predicted sustained AKI, worsening AKI or death. HNL/NGAL in 
plasma was not predictive of AKI in patients with septic shock since sepsis per se 
increased plasma levels of HNL/NGAL. Urinary HNL/NGAL was less affected by 
sepsis and performed well as an AKI predictor. In combination, our two ELISAs 
effectively distinguished monomeric HNL/NGAL, released from kidney tubular cells, 
from dimeric HNL/NGAL, mainly released by activated neutrophils, during the 
development of AKI. 
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ABBREVIATIONS 
ADQI Acute Dialysis Quality Initiative 
AKI Acute kidney injury 
AKIN Acute Kidney Injury Network 
APACHE Acute Physiology And Chronic Health Evaluation 
ARF Acute renal failure 
ATN Acute tubular necrosis 
AuROC Area under the receiver operating characteristics curve 
CKD Chronic kidney disease 
CRP C-reactive protein 
ELISA Enzyme-linked immunosorbent assay 
ESKD End-stage kidney disease 
GFR Glomerular filtration rate 
HNL Human neutrophil lipocalin 
ICU Intensive care unit 
IL Interleukin 
KIM Kidney injury molecule 
LMWP Low-molecular-weight protein 
MDRD Modification of Diet in Renal Disease 
MMP Matrix metalloproteinase 
NAG N-acetyl-β-d-glucosaminidase 
NFP Net filtration pressure 
NGAL Neutrophil gelatinase-associated lipocalin 
PCT Procalcitonin 
RIA Radioimmuno assay 
RIFLE Risk, Injury, Failure, Loss of kidney function, End-stage kidney 
disease 
ROC Receiver operating characteristics 
RRT Renal replacement therapy 
SIRS Systemic inflammatory response syndrome 
TBW Total body water 
TLR Toll-like receptor 
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INTRODUCTION 
An acute decline in the kidneys’ ability to filter water and waste products commonly 
occurs in critically ill patients treated in the intensive care unit (ICU).  It is reasonable 
to assume that this functional impairment is preceded by structural damage to the 
kidney epithelium, triggered by factors such as sepsis, major surgery and nephrotoxic 
drugs. This process, known as acute kidney injury (AKI) is strongly associated with 
increased mortality and survivors are predisposed to develop chronic kidney disease 
(CKD) sometimes progressing to lifelong dialysis dependency. While the prognosis of 
acute myocardial injury has improved over the years owing to the parallel identification 
of early biomarkers (e.g. troponins) of cardiac tissue damage, the recognition of AKI 
still relies on functional markers such as a rising plasma level of creatinine or a decline 
in urine output. These are late and unreliable measures and often do not indicate the 
injury before it is beyond repair.  
 
A better understanding of the pathophysiology of AKI has emerged in recent years. 
Promising treatment strategies instituted before AKI is indicated by a rise in creatinine 
have been demonstrated in animal studies. In humans, however, efforts to treat AKI 
have been unsuccessful so far. An important reason for this therapeutic failure has been 
the lack of biomarkers, which detect the early stages in the AKI process. Several 
promising biomarkers have been identified, as representing different 
pathophysiological signals during the AKI continuum. Many of these biomarkers have 
shown excellent properties for the early detection of AKI. The performance has, 
however, been inconsistent in the studies. Before any biomarker can be introduced as a 
clinical tool in the ICU, it must be assessed in the presence of different critical 
conditions, e.g. in sepsis and after severe trauma.  
 
This thesis focuses on human neutrophil lipocalin/neutrophil gelatinase-associated 
lipocalin (HNL/NGAL) and cystatin C as potential markers of AKI and kidney 
function, respectively. The impact of sepsis on the concentration of these biomarkers in 
plasma and urine is investigated as well as their ability to predict AKI and/or mortality 
in ICU patients. Finally, the ability of two enzyme-linked immunosorbent assays 
(ELISAs) to quantify the different molecular forms of HNL/NGAL released from 
kidney epithelial cells and neutrophils, respectively, is studied.  
  Background 
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BACKGROUND 
DEFINITION OF ACUTE KIDNEY INJURY 
Acute renal failure (ARF) is a continuum of severity stages of kidney dysfunction 
ranging from a reversible decline in the glomerular filtration rate (GFR) to sustained 
ARF with anuria, which may progress to chronic renal failure. Plasma creatinine levels 
and changes in urine output have been used to define ARF for decades. The absence of 
a uniform definition has, however, impeded the ability to compare preventive 
strategies, therapies and outcomes in different studies.1 In 2004 the Acute Dialysis 
Quality Initiative (ADQI) Group developed a new definition for ARF, called the Risk 
(R), Injury (I), Failure (F), Loss of kidney function (L) and End-stage kidney disease 
(E) (RIFLE) criteria.2  Later, the term acute renal failure was replaced by acute kidney 
injury (AKI), reflecting the fact that structural injury most certainly precedes an acute 
decline in kidney function.3  
 
The RIFLE criteria define AKI according to three stages of increasing severity (R, I 
and F) and two outcome criteria based on the duration of renal replacement therapy (L 
and E). The R, I and F classes are based on either a relative increase in plasma 
creatinine from baseline or an episode of oliguria (Table 1).  
 
In 2007, the Acute Kidney Injury Network (AKIN) Group published a slightly 
modified version of the RIFLE criteria.4 In the AKIN criteria, the outcome classes L 
and E were omitted and classes R, I and F were replaced by AKIN stages 1, 2 and 3. 
Based on findings that even small increments in creatinine are associated with adverse 
outcomes,5, 6 an absolute increase of ≥ 26.4 µmol/l was included in stage 1. Patients 
starting renal replacement therapy (RRT) were included in stage 3, regardless of urine 
output or creatinine level. 
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Table 1. Definition and staging of AKI according to the Risk, Injury, Failure, Loss and End-stage kidney 
disease (RIFLE) criteria with modifications proposed by the Acute Kidney Injury Network (AKIN) 
Group. 
AKI severity Plasma creatinine criteria Urinary output criteria 
RIFLE   
Risk ≥ 1.5-fold increase in serum creatinine 
from baseline† 
 
< 0.5 ml/kg/h for ≥ 6 h 
Injury ≥ 2.0-fold increase in serum creatinine 
from baseline† 
 
< 0.5 ml/kg/h for ≥ 12 h 
Failure ≥ 3.0-fold increase in serum creatinine 
from baseline†,‡ 
 
< 0.3 ml/kg/h for ≥ 24 h  
or anuria ≥ 12 h 
Loss of kidney function Complete loss of kidney function > 4 
weeks 
 
 
End-stage kidney disease End-stage kidney disease > 3 months  
AKIN   
Stage 1 ≥ 1.5-fold increase in serum creatinine 
from baseline† or an absolute rise in serum 
creatinine of ≥ 26.4 µmol/l within 48 h 
 
< 0.5 ml/kg/h for ≥ 6 h 
Stage 2 ≥ 2.0-fold increase in serum creatinine 
from baseline† 
 
< 0.5 ml/kg/h for ≥ 12 h 
Stage 3 ≥ 3.0-fold increase in serum creatinine 
from baseline†,‡ or initiation of renal 
replacement therapy 
< 0.3 ml/kg/h for ≥ 24 h  
or anuria ≥ 12 h 
†When baseline creatinine is unknown it is recommended to estimate baseline using the simplified 
Modification of Diet in Renal Disease (MDRD) equation,7 assuming a GFR of 75 ml/min/1.73 m2.2 
‡Patients with chronic kidney dysfunction reach class Failure or Stage 3 when creatinine increases ≥ 44 
µmol/l from baseline to > 350 µmol/l. 
 
INCIDENCE OF ACUTE KIDNEY INJURY 
The incidence of AKI varies across studies depending on the definitions used and the 
populations studied. In 20,126 patients admitted to a tertiary hospital in Australia, 
almost 20% developed AKI defined by the RIFLE criteria.8 In the ICU, the RIFLE 
criteria are fulfilled in 10–70% of patients, depending on the cohort under study.9 After 
cardiac surgery the reported incidence is 19–45%.10, 11 Approximately 4–5% of general 
ICU patients are treated with RRT in the ICU.12 The population incidence of severe 
AKI treated with RRT has increased over the last few decades and reached around 250 
per million population/year at the beginning of this decade.13-16 This is roughly 
comparable with the population incidence of acute lung injury.17 The overall population 
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incidence of AKI is ten-fold higher13, 16 with a magnitude similar to that of severe 
sepsis.18, 19 
 
OUTCOMES OF ACUTE KIDNEY INJURY 
An increasing RIFLE stage is associated with increased length of ICU and hospital 
stay, higher mortality and higher health care costs.9 Hospital mortality in a large ICU 
cohort was 8.8% in patients with RIFLE R, 11.4% in I and 26.3% in F. The 
corresponding mortality in non-AKI patients was 5.5%.20 Uchino et al. found an 
increased in-hospital mortality risk (odds ratio), adjusted for a number of covariates, of 
2.5, 5.4 and 10.1 in RIFLE R, I and F, respectively.8 Even smaller absolute (26.4 
µmol/l) or relative (25%) increases in creatinine are associated with adverse outcomes.6 
The reported mortality for patients treated with RRT in a Swedish general ICU was 
46% after 30 days, reaching 60% after six months.21 
 
Renal recovery is an important outcome measure in critically ill patients with AKI. Bell 
et al. showed that, among RRT-treated ICU survivors, 8–16% ended up in chronic 
dialysis.22  Interestingly, in 2–4% of patients in whom RRT was successfully 
discontinued after ICU discharge, end-stage kidney disease (ESKD) later developed. 
The incidence of complete renal recovery (i.e. return to baseline GFR) in survivors has 
not been fully investigated. Information about the patients’ baseline GFR is often 
missing and accurate GFR measurements (e.g. using iohexol-clearance) after ICU 
discharge are lacking in most studies. Schiffl et al. followed 226 survivors with RRT-
treated AKI and found a complete recovery of GFR, estimated by creatinine, in 86% in 
patients surviving after 5 years.23 
 
RISK FACTORS FOR ACUTE KIDNEY INJURY 
The causal relationship between biological mechanisms and the structural and 
functional changes in AKI are difficult to investigate in humans, partly because kidney 
biopsies are rarely performed in ICU patients. Instead, we have to rely on associations 
between potential risk factors and AKI. Often multiple factors (patient-specific, 
treatment-specific or the effect of certain conditions commonly seen in the ICU, e.g. 
rhabdomyolysis, post-cardiac surgery and sepsis) act together to cause AKI in the ICU. 
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Patient-specific risk factors 
Patient-specific risk factors include co-morbidities (e.g. diabetes mellitus, CKD, heart 
failure), advanced age and possibly certain gene polymorphisms.24, 25 Especially, an 
increased risk of AKI in CKD patients is highlighted in several studies.26 However, a 
similar or even higher in-hospital mortality in AKI patients without than in those with 
pre-existing CKD has been demonstrated.12, 16, 27 This casts some doubt on CKD as a 
true risk factor for AKI. The observed associations between CKD and high AKI 
incidence might be confounded for several reasons.28 First, valid measurements of 
baseline kidney function are absent in many studies. Second, other risk factors for AKI 
such as diabetes and heart failure are common in CKD. Finally, inclusion of RRT 
requirement in the AKI definition may produce a selection bias since CKD patients are 
likely to have high serum creatinine, a common RRT indication. 
 
Treatment-specific risk factors 
Nephrotoxic drugs contribute to almost 20% of severe AKI cases in ICU patients.12 
Some drugs like aminoglycosides and contrast dye are innately nephrotoxic and exert 
their effect by impairing mitochondrial function, increasing oxidative stress or forming 
free radicals. Contrast-induced nephropathy is reported as one of the most prevalent 
causes of AKI in hospitalized patients.29 Drugs such as vancomycin may induce an 
immune response in the kidney interstitium leading to interstitial nephritis. 
 
Rhabdomyolysis 
Bywaters and Beall discovered the association between crush injury and renal 
impairment in 1941.30 Rhabdomyolysis is characterized by the breakdown of skeletal 
muscle with the release of muscle-cell contents, including myoglobin, into the 
bloodstream. The reported incidence of AKI in rhabdomyolysis is substantial (13–
50%).31 Most patients with rhabdomyolysis-induced AKI do, however, recover their 
kidney function.32 Several mechanisms interact in rhabdomyolysis-induced AKI. 
Myoglobin is a 17-kDa oxygen-carrying heme protein that contains ferrous (Fe2+) 
oxide. Myoglobin is completely reabsorbed and metabolized by the proximal tubule 
after free glomerular filtration but appears in urine if the reabsorptive capacity is 
exceeded. Oxidation of ferrous to ferric (Fe3+) oxide promotes the generation of free 
oxygen radicals that cause proximal tubular damage. Myoglobin can also precipitate 
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and form heme-pigment casts within the tubular lumen, eventually leading to tubular 
obstruction. These processes are enhanced by intravascular volume depletion and an 
acidic tubular milieu. Circulation of inflammatory mediators and activation of the 
immune system may also play a role.31 
 
Cardiac surgery 
Cardiac surgery is the second most common trigger of AKI.12 Several mechanisms 
behind this association have been suggested with a focus on the impact of the 
cardiopulmonary by-pass (CPB) circuit.33 Pump-induced haemolysis with the release of 
free iron has been suggested. Free iron is toxic to the tubular epithelium and may 
impair cell proliferation and hence the repair process in AKI.34  The formation of free 
oxygen radicals catalysed by free iron addressed in the previous section may also be a 
feature of CPB-induced AKI. 
 
Sepsis and the systemic inflammatory response 
The word sepsis is used to describe the syndrome of systemic inflammation when 
infection is the cause.35 Severe sepsis refers to conditions when sepsis is complicated 
by organ failure and septic shock is characterized by hypotension resistant to volume 
resuscitation. An annual increase of sepsis cases close to 9% has been reported from the 
United States over the last decades.19 ICU mortality in patients with severe sepsis and 
septic shock was above 30% and 50%, respectively, in a multi-centre study from 
Europe.36 The inflammatory response is important to survive a severe infection but may 
also cause organ damage. The innate immune system is the first line of defence against 
invading microbial pathogens. Toll-like receptors (TLRs) are located on the cell surface 
of many human cell types and recognize unique structures on the cell wall of 
microorganisms. Binding to TLRs rapidly induces the production and release of pro-
inflammatory (e.g. TNF-α and IL-1β) and anti-inflammatory (e.g. IL-10) cytokines and 
chemokines. Alternatively, activation of TLRs directs the cell towards apoptosis. Pro-
inflammatory cytokines up-regulate adhesion molecules on endothelial cells and, 
together with chemokines, facilitate recruitment and adhesion of neutrophils to the 
endothelium. Subsequent release of prostaglandins, leukotrienes, proteases and 
oxidants from activated immune cells impairs the key functions of the endothelium, 
namely its selective permeability, vasoregulation and provision of an anticoagulant 
Johan Mårtensson   
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surface. Hence, widespread endothelial injury results in vasodilation, increased vascular 
permeability and coagulopathy with the risk for microthrombi formation. Vasodilation 
is further enhanced by increased synthesis of nitric oxide (NO).37 Severe sepsis is the 
most common AKI trigger in ICU patients, contributing to approximately 50% of 
cases. Besides, septic AKI is associated with higher mortality and prolonged length of 
stay as compared to non-septic AKI.12, 38 
 
PATHOPHYSIOLOGY OF ACUTE KIDNEY INJURY 
Tubular injury 
The pathophysiology of human AKI is not fully understood. Instead, we rely on animal 
models to solve pieces of the AKI puzzle. The traditional view of AKI, and its cause, 
has been focused on renal ischaemia, triggered by haemodynamic instability and 
subsequent renal vasoconstriction, resulting in acute tubular necrosis (ATN). Lately, 
the concept of tubular ischaemia as the sole explanation for AKI, especially in sepsis, 
has been challenged.39  
 
Regardless of the type of insults (ischaemia, endotoxins, nephrotoxic agents) behind 
different forms of AKI, inflammation seems to play a key role in the 
pathophysiology.40 The kidney insult initiates a pro-inflammatory response in the 
proximal tubular and endothelial cells, resulting in the release of cytokines and 
chemokines. Vasodilation, increased vascular permeability and up-regulation of 
adhesion molecules (e.g. P-selectin) in peritubular capillaries facilitate recruitment and 
subsequent migration of inflammatory cells (neutrophils, lymphocytes and 
macrophages) into the kidney interstitium. During transmigration, the neutrophils 
release their granular contents, including cytokines, causing further damage to the 
kidney epithelium.41-44  
 
Injured tubular cells detach from the underlying basement membrane when cytoskeletal 
integrity and cell polarity is lost.45 If the injury is severe enough, viable as well as 
apoptotic and necrotic cells are desquamated into the tubular lumen, leaving parts of the 
basement membrane denuded. This could potentially allow back leak of fluid, causing 
interstitial oedema.46  
 
  Background 
 
 9 
In response to injury, adjacent viable tubular cells initiate an immediate repair process. 
Repair either successfully restores the functional integrity of the nephron or result in 
fibrotic lesions and chronic kidney dysfunction. Normal repair includes migration and 
division of surviving cells to replace lost cells, so-called de-differentiation (Figure 1). 
Finally, these cells re-differentiate and regain cytoskeletal integrity and polarity.47 
Delivery of iron to tubular cells appears to be involved in this process.48 
 
 
Figure 1. Pathophysiological mechanisms of acute kidney injury and repair. Adhesion molecules up-
regulate on the surface of endothelial cells and facilitate migration of neutrophils into the kidney 
interstitium and tubular lumen. Inflammatory and vasoactive mediators and reactive oxygen species 
(ROS) damage the tubular cells. Shedding of the proximal tubule brush border, loss of polarity with 
mislocation of Na+/K+-ATPase as well as apoptosis and necrosis may occur. With severe injury, viable 
and non-viable cells are desquamated, leaving parts of the basement membrane denuded. Inflammatory 
and vasoactive substances released from the injured tubular cells worsen the pathophysiological changes. 
If the repair process is successful, viable cells de-differentiate and spread to cover exposed areas of the 
basement membrane and restore the functional integrity of the nephron. AC, apoptotic cell; DC, de-
differentiating cell; NC, necrotic cell. 
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Impaired glomerular filtration 
Filtration of water and solutes in the kidneys depends on the net filtration pressure 
(NFP) over the glomerular filtration barrier and the unique properties of the filtration 
barrier itself. NFP is the driving force for filtration which is mainly determined by the 
systemic blood pressure and by the relative tone in the afferent and efferent arterioles 
and is opposed by the oncotic pressure (determined mainly by the albumin 
concentration) in plasma and the hydrostatic pressure in Bowman’s space. The 
magnitude of the normal renal blood flow (~25% of cardiac output) is in excess of the 
kidney’s metabolic needs in order to maintain a high GFR. Despite fluctuations in 
systemic arterial pressure that would be expected to influence NFP, GFR changes very 
little in the healthy kidneys. This is a consequence of intrarenal autoregulation, 
whereby the resistance in the afferent arterioles, and hence the NFP, changes as the 
systemic blood pressure changes. Two mechanisms underlying autoregulation have 
been proposed: (1) the afferent arteriolar wall contracts in response to being stretched 
when the blood pressure increases, the so-called myogenic reflex; (2) GFR initially 
increase in response to increased blood pressure, leading to an increased salt delivery to 
the ‘salt-detecting’ macula densa cells in the distal part of the nephron. The increased 
need for tubular reabsorption of salt is energy consuming and it is followed by the 
release of signalling substances (e.g. adenosine) which contract the afferent arteriole 
thereby blunting the increase in renal blood flow and GFR, so-called tubulo-glomerular 
feedback. These autoregulatory mechanisms hence allow GFR to be maintained across 
a wide range of mean arterial pressures (80–180 mmHg). Outside the autoregulatory 
range, e.g. in circulatory shock, renal blood flow and GFR change with blood pressure. 
 
To enter Bowman’s space, water and solutes must pass through the fenestrated 
endothelium, basement membrane and the slit-pores between podocytes (specialized 
cells lining the glomerular capillaries; Figure 2).  
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Figure 2. Schematic illustration of the glomerular barrier. The barrier is negatively charged and obstructs 
the passage of negatively charged proteins such as albumin. In the healthy kidney only small amounts of 
albumin pass through the glomerular filter. The albumin concentration [Albumin] in plasma and 
glomerular filtrate is shown. 
 
The fenestrated endothelium is size-selective and could theoretically allow passage of 
molecules up to a diameter of 8 nm (80 Å). Yet, albumin has a diameter of 6 nm and 
still only < 0.1% is filtered. This is because the filtration barrier is negatively charged. 
Since many plasma proteins are negatively charged they will be more or less repelled 
by the filter membrane.49 Mesangial cells are also found in the renal glomerulus and 
have features similar to smooth muscle cells. These cells are targets for vasoactive 
substances and are able to regulate the filtration area and hence GFR.50 
 
What impairs GFR and when it occurs during the AKI process is not fully understood. 
Decreasing GFR is a physiological response to haemodynamic instability/low blood 
pressure and can occur without injury to the kidney epithelium. A low GFR is also the 
major functional event of AKI. Despite this fact, current research has focused on 
tubular rather than glomerular injury when attempting to explain decreased GFR in 
AKI. Renal histopathology has been investigated in AKI patients and, surprisingly, 
despite a complete loss of kidney function in some of these patients, only moderate 
structural changes have been observed.51-53 The mechanisms behind the AKI related 
decrease in GFR might well be other than structural changes. Recently, alterations in 
renal haemodynamics and functional changes in the tubules, have been proposed to be 
important factors.   
!
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Mislocation of tubular Na+/K+-ATPase, resulting in impaired sodium reabsorption, has 
been observed in AKI.45 Consequently, increased sodium delivery to the macula densa 
will enhance the tubulo-glomerular feedback, reducing GFR and salt delivery to 
dysfunctional tubular cells. Interestingly, in a septic AKI model, global renal blood 
flow was markedly increased despite a significant reduction of GFR.54 A more 
pronounced vasodilation in efferent as compared to afferent arterioles, resulting in a 
lower NFP, may explain this. The injured kidney endothelium responds more 
vigorously to endogenous vasopressors and less to vasodilators. Together with the 
formation of microthrombi and tissue oedema, microvascular congestion may follow. 
Finally, tubular obstruction by desquamated cells as well as dysfunction of the charge- 
and size-selectivity of the glomerular filtration barrier may be involved in AKI.46, 55  
 
BIOMARKERS OF ACUTE KIDNEY INJURY 
In general, the purpose of a biological marker (biomarker) is to measure pathological 
processes or pharmacological responses to therapeutic interventions.56 So far, efforts to 
treat AKI have failed in humans.57 A very important reason is the lack of markers to 
identify the early pathological processes at a time-point when treatment might be 
successful. This section compares the strengths and weaknesses of creatinine and 
cystatin C in plasma as functional markers of GFR. Furthermore, some promising novel 
biomarkers of acute kidney injury are summarized.  Their potential roles in the 
pathophysiology of AKI will be outlined.  
 
Creatinine 
In 1886 Max Jaffé observed the red colour formed when creatinine reacted with picric 
acid.58 The Jaffé reaction has withstood the test of time and is still in use. The use of 
creatinine as a marker of GFR was investigated for the first time by Poul Brandt 
Rehberg, who in 1926 studied renal clearance of orally administered creatinine.59 
Determination of endogenous creatinine clearance was, however, precluded until 
1938.60 Creatinine is a 113-Da amino acid compound derived from the conversion of 
creatine in skeletal muscle. Creatine is mainly synthesized in the liver, but is also 
supplied from our diet (mainly meat). Muscle contains 98% of the total creatine pool in 
the body. The conversion to creatinine is a relatively stable process that is proportional 
to the total muscle-cell mass. Creatinine is distributed throughout the total body water 
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(TBW), it is not protein-bound and it is mainly excreted via glomerular filtration. There 
are several limitations to the use of plasma creatinine as a marker of GFR, especially in 
ICU patients. First, a rapid loss of muscle mass is common in critically ill patients 
probably as an effect of immobilization61 and/or catabolism.62 A decreasing creatine 
pool, resulting in lowered plasma creatinine levels over time, could, theoretically, be a 
consequence of this. Second, increased tubular secretion compensates a fall in GFR and 
plasma creatinine may not rise until GFR is halved. Extrarenal clearance, via intestinal 
elimination, may also be substantial when GFR is reduced.63 Third, owing to its large 
distribution volume (TBW), it takes time before steady state is reached after rapid 
changes in kidney function or hydration status. Forth, creatinine production and release 
into plasma depends on many non-renal factors (e.g. muscle mass, liver function and 
dietary intake) and results in individual variations in baseline creatinine.  Fifth, 
pathological conditions can increase (e.g. rhabdomyolysis) or decrease (e.g. liver 
failure) plasma levels independently of kidney function.63 Finally, the drawbacks of the 
Jaffé reaction must also be acknowledged. Pseudocreatinines (e.g. ketone bodies, 
glucose, cephalosporins) may significantly affect the colorimetric reaction and give 
falsely elevated creatinine readings. This might have an impact when kidney function is 
monitored in critically ill patients. 
 
GFR measuring from endogenous creatinine clearance does not offer an advantage over 
serum creatinine alone. GFR can be estimated by calculating endogenous creatinine 
clearance (ClCr) from: 
 
ClCr (ml/min) = UCr × V/PCr, 
 
where UCr and PCr are the creatinine concentration in urine and plasma, respectively, 
and V is the urinary flow rate. When GFR falls, PCr will initially be unchanged and UCr 
will increase due to increased tubular secretion, hence ClCr will overestimate GFR. 
Errors in the measurement of urine volume will also limit the accuracy. 
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Cystatin C 
Cystatin C is a 13-kDa molecule considered to be produced by all nucleated cells at a 
constant rate, unaffected by such factors as muscle mass and diet. Being a potent 
inhibitor of cysteine proteases, it prevents breakdown of extracellular proteins. After 
free filtration, cystatin C is reabsorbed and subsequently catabolized by the proximal 
tubular cells. Hence, cystatin C has many potential features of an ideal marker of GFR. 
Indeed, several studies have shown that cystatin C outperforms creatinine as a marker 
of GFR in stable patients.64-66 
 
A number of non-renal factors affecting cystatin C levels in plasma have recently been 
identified, however. Glucocorticoid treatment increases cystatin C levels in a dose-
dependent manner.67-69 Thyroid dysfunction must also be taken into account when 
interpreting cystatin C results since the levels increase in hyperthyroid and decrease in 
hypothyroid patients.70 Restoration of thyroid function seems to normalize cystatin C 
concentrations.71 
 
Cystatin C is more than 100 times larger than creatinine. Small reductions in the 
glomerular pore size might impair the passage of cystatin C, whereas smaller 
molecules, like creatinine, pass freely. Therefore, cystatin C could theoretically be more 
sensitive to mild changes in GFR than creatinine. Contradictory to this are the recent 
findings that sepsis and ischaemia induce changes in the glomerular filtration barrier 
which increase clearance of large molecules.55, 72  
 
The performance of cystatin C in plasma in predicting AKI has been investigated in 
various settings and the results from general ICUs have varied widely. In a study by 
Herget-Rosenthal et al., the rise in cystatin C preceded creatinine in ICU patients who 
were developing AKI. In fact, a > 50% rise predicted AKI within 24 h with an area 
under the receiver operating characteristics curve (AuROC) of 0.97.73 Moreover, Nejat 
et al. observed that cystatin C increased before creatinine more often than vice versa in 
AKI patients and predicted sustained AKI with an AuROC of 0.80.74 The ability to 
predict mortality or subsequent need for RRT was, however, moderate (AuROC, 0.61) 
and no better than for creatinine. Royakkers et al. found serum cystatin C to be a poor 
predictor of AKI (AuROC, 0.62) and the need for RRT (AuROC, 0.66).75 Likewise, 
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Perianayagam et al. showed that cystatin C, creatinine and urea in serum as well as 
urine output were equally poor predictors of dialysis requirement or in-hospital 
mortality at the time of nephrology consultations with AKI patients (AuROC, 0.602–
0.665).76 The predictive accuracy of plasma cystatin C was recently reviewed in a 
meta-analysis including 13 studies from a wide range of settings and age groups. The 
overall accuracy was impressively high with an AuROC of 0.96.77 
 
It is controversial as to whether inflammation has an impact on plasma cystatin C 
levels. Lysosomal cysteine proteases are released in response to trauma and sepsis and 
are involved in apoptosis.78, 79 It is possible that the role of cystatin C is to protect cells 
from increased protease activity and cystatin C could, at least in theory, be either up-
regulated or decreased due to consumption. Two large cross-sectional studies found a 
significant association between cystatin C and systemic inflammation measured by 
CRP.80, 81 On the other hand, Grubb et al. found no temporal changes in cystatin C in 
patients with systemic inflammation induced by surgery.82  
 
Filtered cystatin C is, like many low-molecular-weight proteins (LMWPs), 
endocytozed via the megalin receptor located at the apical membrane of proximal 
tubular cells.83 Impaired reabsorption is a feature of AKI and leads to an accumulation 
of cystatin C in the urine. Down-regulation of the megalin receptor probably 
contributes to this. The effect of albuminuria per se on urinary cystatin C levels has 
recently been discussed. Competitive inhibition of the megalin receptor by albumin 
may decrease the tubular uptake of cystatin C (and other LMWPs).84, 85 Sepsis, even 
without AKI, may be associated with albuminuria and could therefore cause elevated 
cystatin C levels in urine. Nejat et al., who found higher urinary cystatin C levels in 
septic as compared to non-septic patients, supported this theory.86 
 
Urinary cystatin C predicted RRT requirement in patients classified as having non-
oliguric ATN with an AuROC of 0.92.87 The performance in predicting AKI was 
investigated in a recent meta-analysis. The pooled AuROC from four studies amounted 
to 0.64.77 
Johan Mårtensson   
 
 16 
Human neutrophil lipocalin/Neutrophil gelatinase-associated lipocalin 
Neutrophil gelatinase-associated lipocalin (NGAL), also known as human neutrophil 
lipocalin (HNL) or lipocalin 2, was first purified from the secondary granules of human 
neutrophils.88, 89 The protein was identified as a 25-kDa monomer, as a 45-kDa 
disulphide-linked homodimer and as a 135-kDa heterodimer, covalently conjugated 
with gelatinase (matrix metalloproteinase (MMP)-9).88, 89 HNL/NGAL is synthesized in 
the bone marrow during myelopoiesis and is directed to and stored in the neutrophil 
granules.90 Mature neutrophils release HNL/NGAL into the bloodstream in response to 
bacterial infections. In fact, significantly higher HNL/NGAL levels in serum and 
plasma are seen in bacterial, as compared to viral, infections.91, 92 HNL/NGAL mRNA 
is also expressed in other human tissues frequently exposed to microorganisms, such as 
colon, trachea, lung and kidney tissues.93 Stimulation with the inflammatory mediator 
IL-1β increased HNL/NGAL synthesis in a number of human cell lines.94 Additionally, 
elevated plasma levels have been observed in several inflammatory conditions such as 
acute peritonitis and acute exacerbations of obstructive pulmonary diseases.95  
 
In the search for novel biomarkers of AKI, HNL/NGAL was among the most up-
regulated genes after ischaemic AKI in animal models.96, 97 The subsequent proteomic 
analyses verified that HNL/NGAL was highly induced in animal kidneys following 
ischaemic and nephrotoxic AKI and that urinary concentrations increased several-fold 
early on (within hours) after the insult.97, 98 An accumulation of HNL/NGAL in serum 
and urine in humans with established AKI was later revealed.99 
 
The first study evaluating HNL/NGAL as an AKI predictor was conducted on children 
after cardiac surgery. Urinary HNL/NGAL rose almost 100-fold and serum 
HNL/NGAL 20-fold up to 48 h before AKI was detected by creatinine. The urinary 
HNL/NGAL level was an almost perfect AKI predictor with an AuROC of 0.998.100 
Since obtaining these encouraging results, the predictive performance of HNL/NGAL 
has been tested in various clinical settings. The results have varied across studies and 
can be ascribed to a number of factors. First, the definition of the outcome variable, i.e. 
AKI, is important. This was shown in one study where the predictive value increased 
with the severity of AKI ranging from an AuROC of 0.65 for the prediction of a > 25% 
increase in creatinine to an AuROC of 0.79 for predicting a rise above 50%.101 Second, 
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inclusion of CKD patients may affect the results since CKD per se is associated with 
elevated serum and urinary HNL/NGAL levels.102, 103 McIlroy et al. found that urinary 
HNL/NGAL only identified AKI after cardiac surgery in patients with an estimated 
baseline GFR of > 90 ml/min.104 Third, the time from HNL/NGAL measurement to 
AKI development differs among studies. It is reasonable to believe that the predictive 
value will be higher if AKI develops within 1 day, rather than within 10 days, from the 
measurement. Forth, co-morbid diseases and conditions such as sepsis might affect 
HNL/NGAL levels independently. In fact, Bagshaw et al. found higher HNL/NGAL in 
plasma and urine in AKI patients with sepsis as compared to non-septic AKI patients 
despite equal AKI severity.105  
 
The predictive performance was recently highlighted in a meta-analysis pooling data 
from 19 studies and eight countries involving 2,538 patients. The overall AuROC for 
AKI prediction was 0.815 and was similar in general ICU patients and after cardiac 
surgery. Moreover, HNL/NGAL measured in urine or plasma/serum performed equally 
well using the proposed cut-off value of 150 µg/l. The predictive ability was better in 
children (AuROC, 0.930) than in adults (AuROC, 0.782), probably reflecting the 
impact of co-morbid illness on HNL/NGAL levels.106 
 
Normally, small amounts of HNL/NGAL are produced by different tissues and released 
into the bloodstream. After free filtration, HNL/NGAL is reabsorbed via megalin-
receptor mediated endocytosis by the proximal tubule.99, 107 Elevated HNL/NGAL 
levels in urine and plasma during early AKI may have several causes (Figure 3): (1) 
impaired reabsorption in the damaged proximal tubule increases urinary levels;99 (2) 
induced synthesis in different parts of the nephron has been demonstrated in animal 
models;99, 108 (3) secretion from neutrophils, migrating from capillaries into the tubular 
lumen, may also be a potential source;41 (4) increased HNL/NGAL mRNA expression 
has been found in distant organs (lung) in animal AKI models.109 Such extra-renal 
production may contribute to elevated plasma levels in AKI. A subsequent decline in 
GFR will further amplify plasma levels. Worth noting is that HNL/NGAL is also 
highly expressed and released by the liver and circulating neutrophils in response to 
inflammation.110, 111 This might increase levels of plasma and urinary HNL/NGAL 
irrespective of any potential kidney damage. Moreover, increased urine levels have 
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been observed in patients with urinary tract infection (UTI), although at lower levels 
than normally seen in AKI.112 
 
 
Figure 3. Proposed mechanisms for increased HNL/NGAL in plasma and urine in AKI. 
 
The results from a recent in vitro study on human tubule epithelial cells (HK-2 cells) 
and neutrophils indicate that kidney epithelial cells mainly secrete monomeric 
HNL/NGAL, whereas neutrophils mainly release the dimeric form detected by Western 
blot.113 The finding that dimeric HNL/NGAL was the predominant form in the urine of 
patients with UTI further supported this possibility. The different forms of HNL/NGAL 
(monomeric, dimeric, heterodimeric) may expose different epitopes. The choice and 
configuration of antibodies directed against different epitopes on the HNL/NGAL 
molecule clearly have an impact on the clinical performance of the assay.114 Notably, 
most studies investigating HNL/NGAL as an AKI predictor use commercial ELISAs 
such as Bioporto (Gentofte, Denmark) and R&D systems (MN, USA). These assays are 
based on monoclonal anti-HNL/NGAL antibodies. The use of different assays may 
contribute to the varying performance of NGAL as an AKI predictor in the studies.106 
Whether HNL/NGAL in urine during AKI is derived from both tubular cells and 
neutrophils, and whether a possible contribution from these sources represent different 
pathophysiological signals during AKI development, has not yet been addressed.  
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Several biological functions for HNL/NGAL have been suggested. By its ability to bind 
siderophores (small iron-binding molecules), HNL/NGAL is involved in the iron 
transport to and from cells.115 Iron is vital for cell survival but may also be toxic owing 
to its ability to catalyse the conversion of hydrogen peroxide to free oxygen radicals. 
Bacteria release siderophores in order to acquire iron from the host. HNL/NGAL acts 
as a bacteriostatic agent by sequestering iron, which is vital for bacterial growth.110, 116 
Neutrophils, which store HNL/NGAL in their granules, provide the organism with a 
mobile source of HNL/NGAL. Furthermore, HNL/NGAL production in epithelial cells 
may be important for the local defence against an infection. Iron is also necessary for 
the proliferation and differentiation of human cells. Yang et al. found that HNL/NGAL 
promoted iron-dependent differentiation of mesenchymal progenitors into complete 
nephrons during the development of the kidneys.48 The renoprotective role of 
HNL/NGAL is supported by animal models of ischaemia-reperfusion-induced AKI, 
where intravenously administered HNL/NGAL was rapidly taken up by proximal 
tubular cells and reduced tubular damage and apoptosis as well as increased cell 
proliferation.99, 117 
 
α1-microglobulin 
α1-microglobulin is a 27-kDa glycoprotein produced by the liver.118 It exists in plasma 
in a free monomeric form but also bound to other proteins, mainly IgA. α1-
microglobulin is found in the connective tissue of most organs.  Its exact biological role 
is still unknown, but anti-inflammatory properties have been suggested. The free form 
is eliminated through glomerular filtration and is then reabsorbed and catabolized by 
the proximal tubular cells. Hence, increased plasma levels are related to impaired 
kidney function, whereas decreased levels are seen in liver failure.118 Free α1-
microglobulin is detected in urine and is a marker of proximal tubular dysfunction.119 
Albuminuria, e.g. in response to systemic inflammation, may increase the urinary 
excretion of α1-microglobulin by competition on the megalin receptor.120, 121 This might 
increase the threshold for detection of AKI. 
 
In one study on non-oliguric patients with established AKI, α1-microglobulin predicted 
the subsequent need for RRT with an AuROC of 0.86.87  
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Kidney injury molecule-1 
Phagocytosis of apoptotic and necrotic cells in the tubular lumen might down-regulate 
the pro-inflammatory response and aid in the repair process during AKI. Kidney injury 
molecule (KIM)-1 is a transmembrane glycoprotein that is up-regulated on the tubular 
epithelial cell surface in response to injury. KIM-1 seems to transform these cells into 
phagocytes which clear the lumen of cellular debris.122 Additionally, KIM-1 is 
expressed in tubular cells undergoing de-differentiation, further supporting its role in 
the repair process after injury.123 Its ectodmain is cleaved and released in urine and can 
be measured as a biomarker of AKI.124 In a recent study KIM-1 outperformed 
creatinine as a predictor of drug-induced tubular damage classified according to 
histopathological changes in rats.125 In a study on six patients with biopsy-proven ATN, 
KIM-1 was highly expressed in the proximal tubules.124 The same study also found that 
urinary KIM-1 was significantly higher in patients with ‘ischaemic’ ATN as compared 
to those with other acute and chronic kidney diseases.  
 
Interleukin-18 
Interleukin (IL)-18 is a pro-inflammatory 18-kDa cytokine produced and secreted by 
proximal tubular cells and leucocytes in AKI.40 Pro-IL-18 is converted to its active 
form by a cysteine protease (caspase-1). The finding that experimental inhibition of IL-
18 in animals protected against ischaemic renal injury supported its role in the 
pathogenesis of AKI.126 Mature IL-18 does not seem to interfere with the megalin-
receptor.85 
 
N-acetyl-β-d-glucosaminidase 
N-acetyl-β-d-glucosaminidase (NAG) is a large (> 130 kDa) lysosomal enzyme found 
in several human cells, including the renal tubules. NAG is the most active glycosidase 
found in proximal tubular epithelial cell lysosomes. It is not filtered over the glomeruli 
and elevated levels in urine are therefore believed to reflect tubular injury. Since 
elevated urinary NAG levels have been shown during several active renal diseases, the 
specificity for AKI might be reduced.127  
 
Although it appears that the above-mentioned urinary biomarkers perform well for the 
diagnosis of established AKI in adult patients,128 their ability to predict AKI are 
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generally less robust. The predictive values have been inconsistent across studies for 
urinary HNL/NGAL (AuROC, 0.50–0.98),129, 130 cystatin C (AuROC, 0.50–0.72),129, 131 
α1-microglobulin (AuROC, 0.62–0.89),129, 132 KIM-1 (AuROC, 0.68–0.78),129, 133 IL-18 
(AuROC, 0.53–0.89)134, 135 and NAG (AuROC, 0.61–0.72).133, 136 These biomarkers 
need further validation in patients with different critical conditions and co-morbidities 
before they can be regarded as clinically useful AKI predictors.  
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AIMS OF THE STUDY 
The general aim was to investigate the performance of different biomarkers and their 
assays in predicting adverse outcomes, i.e. acute kidney injury and mortality, in 
critically ill patients and the impact of sepsis on biomarker levels. Our specific aims 
were: 
1. To study the ability of plasma cystatin C to predict short- and long-term 
mortality in critically ill patients with and without AKI. 
2. To study the impact of sepsis and AKI on HNL/NGAL levels in plasma and 
urine and to test whether the presence of septic shock affects the performance of 
plasma and urinary HNL/NGAL in predicting AKI. 
3. To study the impact of sepsis on cystatin C levels in plasma and to investigate 
the predictive properties of plasma cystatin C for early detection of AKI, the 
need for acute RRT or mortality in ICU patients with and without sepsis. 
4. To examine the ability of two ELISAs to detect HNL/NGAL released in urine 
from kidney epithelial cells and neutrophils respectively.  
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SUBJECTS AND METHODS 
Table 2. Summary of subjects and methods used in Studies I–IV 
 Study I Study II  Study III Study IV 
Data source PRONX, 
Population 
Register 
PEAK PEAK, PROTIVA, 
EXCRETe 
PEAK 
Design Prospective 
cohort study 
Case-control study Prospective cohort 
study 
Prospective cohort 
study 
Study period 2003–2007 2007–2008 2007–2010 2007–2009 
Participants (n) AKI (271) 
Non-AKI (562) 
 
Non-AKI  
SIRS (10) 
Severe sepsis (10) 
Septic shock (7) 
AKI  
Septic shock (18) 
AKI-/sepsis- (151) 
AKI-/sepsis+ (80) 
AKI+/sepsis- (24) 
AKI+/sepsis+ (72)  
 
Urinary HNL/NGAL           
≥ 50 µg/l (47) 
Exposure Plasma cystatin 
C level 
HNL/NGAL in 
urine or plasma  
Sepsis  
or 
Plasma cystatin C 
on ICU admission 
Monomeric/Dimeric 
HNL/NGAL in urine 
Outcome Long-term 
mortality 
AKI Cystatin C change 
or 
Sustained AKI, 
worsening AKI or 
mortality 
ELISA-1 and  
ELISA-2 levels 
Statistical 
analysis 
Cox regression ROC analysis Repeated measures 
ANOVA, ROC 
analysis 
Quantile regression 
 
 
REGISTERS AND DATABASES 
All databases exclusively include patients referred to the general ICU at the Karolinska 
University Hospital Solna. 
 
The Total Population Register (Study I) 
The register contains data from the Swedish census since 1968 and is managed by 
Statistics Sweden. The Swedish national registration number allows identification and 
follow-up of patients in the register with respect to short- and long-term mortality.  
 
The PRONX Database (Study I) 
All consecutive patients admitted to the ICU between June 2003 and November 2007 
were screened for eligibility in the PRONX (PROspektiv Njurstudie på KS) database. 
Inclusion criteria were: (1) plasma creatinine > 150 µmol/l, (2) plasma urea > 25 
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mmol/l or (3) oliguria/anuria (urinary output < 800 ml/24 h or < 30 ml/h for 6 h). 
Patients treated with RRT were excluded. Plasma cystatin C and creatinine were 
measured at inclusion and patients were classified according to the RIFLE criteria. 
For comparison, we retrospectively included ICU patients who did not meet the 
predefined AKI criteria and had cystatin C measured on ICU admission between June 
2006 and November 2007 (non-AKI cohort).  
 
The PEAK Database (Studies II–IV) 
Patients with a GFR > 60 ml/min/1.73m2 on admission, estimated by the simplified 
MDRD formula,7 and an expected ICU length of stay of more than 24 h were included 
in the Predicting Early Acute Kidney injury (PEAK) database. Study samples (blood 
and urine) were collected twice daily from admission until discharge or earlier if RRT 
was initiated. Patients were classified according to the RIFLE and AKIN criteria on a 
daily basis using both the creatinine and urinary output criteria (Table 1). If present, 
creatinine values obtained within 48 h before ICU admission, as well as 48 h after ICU 
discharge, were included in the RIFLE/AKIN classification. The presence (or absence) 
of systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis or septic 
shock on each ICU day was recorded in the database (Table 3). Baseline characteristics, 
Acute Physiology And Chronic Health Evaluation (APACHE) II score, ICU diagnosis 
and ICU mortality were recorded. Information about co-morbid conditions and 30-day 
mortality was collected retrospectively from the hospital-based electronic case-record 
system. Physiological parameters (urinary output, arterial blood pressure), biomarker 
concentrations, body weight and information about corticosteroid and antimicrobial 
therapy obtained as a part of routine care procedures were recorded repeatedly during 
the ICU stay. 
 
The PROTIVA Database (Study III) 
All consecutive multi-traumatized patients referred to the ICU were recorded in the 
PROTIVA (PROTeiner på IVA) database. The same routine variables that were 
recorded in the PEAK database were also recorded in the PROTIVA database. 
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The EXCRETe Database (Study III) 
Patients with a GFR < 60 ml/min/1.73m2 on admission, estimated by the simplified 
MDRD formula, or patients in whom RRT was initiated in the ICU were included in 
the EXtracorporeal Clearance & REsidual renal function during rrT (EXCRETe) 
database. Patients with RRT treatment prior to ICU admission were excluded. Routine 
variables obtained during the ICU stay were recorded in the database in the same way 
as for the PEAK and PROTIVA databases. 
 
SCORING METHODS 
Severity of acute kidney injury 
Urine output and plasma creatinine levels were recorded on a daily basis in the PEAK, 
PROTIVA and EXCRETe databases. The lowest creatinine level found within 3 
months prior to ICU admission was used as baseline for the individual creatinine-based 
RIFLE/AKIN classification (Table 1). When no true pre-admission creatinine value 
was available, baseline creatinine was estimated by the MDRD equation using a low 
normal value for GFR (75 ml/min/1.73 m2).  
 
SIRS/sepsis scoring 
The SIRS and sepsis classifications used in Studies II-IV are detailed in Table 3.35  
 
Table 3. SIRS and sepsis scoring. 
SIRS ≥ 3 of the following criteria: 
1. Body temperature > 38˚C or < 36˚C 
2. Heart rate > 90 beats/min 
3. Respiratory rate > 20 breaths/min or PaCO2 < 4.3 kPa 
4. White blood cell count > 12 or < 4 x 109 cells/l 
 
Sepsis SIRS together with a suspected infection 
 
Severe sepsis Sepsis together with ≥ 1 of the following criteria: 
1. PaO2/FiO2 ratio < 27 
2. Urine output < 0.5 ml/kg/h during > 1 h 
3. Platelet count < 80 x 109 cells/l or a > 50% decline over 3 days 
4. Arterial pH ≤ 7.30 
5. Base deficit ≥ 5 mmol/l in association with hyperlactatemia (> 3 mmol/l) 
 
Septic shock Sepsis together with hypotension defined as: 
1. Systolic blood pressure < 90 mmHg or mean arterial pressure < 70 mmHg 
during > 1 h despite adequate fluid resuscitation* or 
2. Need for vasopressor agents despite adequate fluid resuscitation* 
PaCO2, partial pressure of arterial carbon dioxide; PaO2, partial pressure of arterial oxygen; FiO2, fraction of 
inspired oxygen. *≥ 20 ml cristalloid/kg body weight or ≥ 10 ml colloid/kg body weight. 
Johan Mårtensson   
 
 26 
The modification of the SIRS criteria applied by the Protein C Worldwide Evaluation 
in Severe Sepsis (PROWESS) study group was also applied by us, i.e. at least three 
(instead of two) out of four criteria had to be fulfilled.137  
 
LABORATORY ASSAYS 
Blood samples taken as a part of routine care were analysed at the Department of 
Clinical Chemistry, Karolinska University Hospital Solna. Study samples (PEAK 
database) were immediately centrifuged at 2,000 rpm at 4˚C for 10 min. The 
supernatant plasma and urine were aliquoted into cryovials and stored at -80˚C and 
were later analysed at the Department of Clinical Chemistry, Uppsala University 
Hospital, Uppsala, or by Diagnostics Development (Uppsala, Sweden). Plasma samples 
were analysed for HNL/NGAL, procalcitonin (PCT), C-reactive protein (CRP), 
myeloperoxidase (MPO) and cystatin C. Urine samples were analysed for HNL/NGAL, 
creatinine, cystatin C and α1-microglobulin. Assay characteristics are described in detail 
below and in Table 4. 
 
HNL/NGAL immunoassays 
Radioimmuno assay (RIA) 
HNL/NGAL in plasma (Study II) and urine (Studies II and IV) were quantified by RIA. 
50 µl of plasma or urine was mixed with 50 µl of 125I-labelled HNL/NGAL (diluted to 8 
µg/l in a dilution buffer) and 50 µl of rabbit anti-HNL/NGAL polyclonal antibodies 
(diluted 1/3,800 in assay buffer) and incubated for 3 h at room temperature. Thereafter, 
500 µl of solid phase cellulose suspension containing secondary antibodies (anti-rabbit 
IgG) were added and the incubation was continued for 1 h at 4˚C. HNL/NGAL-
antibody complexes bound on anti-rabbit IgG coated cellulose were separated by 
centrifugation at 3,400 rpm for 15 min. After decantation, the radioactivity was 
measured in a gamma counter. The intra- and inter-assay coefficients of variation 
(CVs) were < 6% and < 10%, respectively. Expected normal HNL/NGAL levels were 
< 73.5 µg/l in plasma and < 141 ng/mg creatinine in urine. 
 
Western blot 
The different molecular forms of HNL/NGAL in urine were detected by Western 
blotting in Study IV. 20 µl of urine were applied to Nu-PAGE® 4–12% Bis-Tris Gel 
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(Invitrogen Corporation, USA). After exposure to sodium dodecyl sulphate (SDS) and 
electrophoresis, proteins were transferred to a Hybone-P polyvinylidene fluoride 
(PVDF) membrane (GE Healthcare, UK) using Nu-PAGE® transfer buffer at 25 V for 
1 h. Additional binding sites of the PVDF membrane were blocked by a blocking 
solution (GE Healthcare, UK) for 1 h. Thereafter, the blots were incubated with rabbit 
anti-HNL/NGAL polyclonal antibodies for 1 h. Finally, the blots were incubated for 45 
min with peroxidase-conjugated secondary antibodies (GE Healthcare, UK). 
Immunoblots were detected by enhanced chemiluminiscence. 
 
Enzyme-linked immunosorbent assay (ELISA) 
Microtiter plates (Nunc Maxsorp, Agogent, Denmark) were coated with a monoclonal 
anti-HNL/NGAL antibody (clone 763; Diagnostics Development, Uppsala, Sweden) at 
4˚C overnight. Additional binding sites were blocked with carbonate-bicarbonate buffer 
(Invitrogen Corporation, UK) at 37˚C for 1 h. 100 µl of urine diluted in assay solution 
were added in duplicates and incubated for 2 h at room temperature. 100 µl of diluted 
monoclonal anti-HNL/NGAL antibodies (clones 754 or 765) were added and incubated 
at room temperature for 1 h, followed by incubation with 100 µl of diluted horseradish 
peroxidase-conjugated antibodies (GE Healthcare, UK) during another 1 h at room 
temperature. Finally, 100 µl of tetramethylbenzidine solution were added to visualize 
the enzyme reaction. Absorbance was measured by a microplate-reader 
(SPECTRAmax 250, GMI, Inc., USA). 
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Additional assays 
Table 4 summarizes the additional biomarkers, and their assay characteristics, analysed 
in Studies I–IV.  
 
Table 4. Additional biomarkers presented in Studies I–IV. 
Biomarker Study Immunoassay Analyser Total CV% Expected normal 
Plasma      
Creatinine1 I–IV Alkaline picrate 
colorimetry 
 
LX/DxC 800a 4–9% < 100 µmol/l (men) 
< 90 µmol/l (women) 
Cystatin C1 I, III Turbidimetric LX/DxC 800a 7% (1.0 mg/l) 
3.9% (3.4 mg/l) 
 
< 0.99 mg/l 
Cystatin C2 II Turbidimetric Architect 
Ci8200b 
1.7% (0.77 mg/l)  
1.1% (1.25 mg/l) 
 
< 1.55 mg/l (>50 yr) 
< 1.20 mg/l (<50 yr) 
CRP2 II Turbidimetric Architect 
Ci8200b 
 
4% < 5 mg/l 
CRP1 III Turbidimetric LX/DxC 800a 
 
4–5% 
 
< 3 mg/l 
PCT2 II ELISA Cobas EEc 6% (0.25 µg/l)  
3% (10.4 µg/l) 
 
< 0.05 µg/l 
MPO3 II ELISA SPECTRA- 
max 250d 
< 6% < 55.4 µg/l 
Urine      
Creatinine2 II Alkaline picrate 
colorimetry 
Architect 
Ci8200b 
5% (56 µmol/l)  
3% (370 µmol/l) 
 
2.5–16.4  
mmol/24 h 
Cystatin C2 II Turbidimetric Architect 
Ci8200b 
2.96% (0.13mg/l)  
2.67% (0.9 mg/l) 
 
< 6.2  
mg/g creatinine 
α1- 
microglobulin2 
II Turbidimetric Architect 
Ci8200b 
6% (36 mg/l)  
9% (48 mg/l) 
< 6.2  
mg/g creatinine 
1Department of Clinical Chemistry, Karolinska University Hospital Solna, Sweden; 2Department of 
Clinical Chemistry, Uppsala University Hospital, Uppsala, Sweden; 3Diagnostics Development, 
Uppsala, Sweden; aBeckman-Coulter, CA, USA; bAbbott Laboratories, Abbott Park, IL, USA; cRoche 
Diagnostics, Mannheim, Germany; dGMI, Inc., USA.	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STUDY I 
Design and study population 
A total of 271 patients entered the AKI cohort in the PRONX database and 562 patients 
were included in the non-AKI cohort. 124 non-AKI patients had creatinine > 100 
µmol/l or urea > 20 mmol/l and were classified as having a ‘potential’ AKI. The AKI 
cohort was stratified into four quartiles according to their cystatin C and creatinine 
levels at inclusion, i.e. at the time when the AKI criteria were met. AKI patients were 
also categorized into four groups based on their RIFLE stage (zero, R, I or F) at 
inclusion. The non-AKI patients were first divided into four quartiles according to their 
cystatin C level on ICU admission. Secondly, the patients in the highest quartile were 
divided into two separate groups.  Information about long-term mortality was obtained 
from the Population Register. 
 
Statistical analysis 
The association between cystatin C strata and long-term mortality was estimated by 
hazard ratios (HRs) derived from the Cox proportional hazards regression model before 
and after adjustment for covariates. Cumulative survival curves were generated using 
the Kaplan-Meier methodology and differences between survival curves were 
examined using the log-rank test.  
 
STUDY II 
Design and study population 
Sixty-five patients were included in the PEAK database between August 2007 and 
November 2008 and were assessed for eligibility in Study II. Non-AKI patients were 
categorized according to their worst SIRS/sepsis score in the ICU into: (1) SIRS (n = 
10), (2) severe sepsis (n = 10) or (3) septic shock (n = 7). For comparison, we included 
a fourth category comprising AKI patients with septic shock (n = 18). Peak levels in 
plasma for HNL/NGAL, MPO, PCT, CRP, cystatin C and creatinine and in urine for 
HNL/NGAL, α1-microglobulin and cystatin C were compared between the four 
categories. Urinary creatinine was measured and served to correct the urinary 
biomarker levels for variations in urine dilutions. HNL/NGAL levels in plasma and 
urine measured at 12 h before the time-point when AKI was first diagnosed (AKI day 
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0) were compared with the HNL/NGAL concentrations obtained from the fifth 
consecutive plasma and urine sample in non-AKI patients.  
 
Statistical analysis 
The Kruskal-Wallis test was used for overall comparisons of peak biomarker levels 
between the four categories. A post-hoc comparison between two categories was made 
using the Mann-Whitney test. The performance of HNL/NGAL in plasma and urine in 
predicting AKI within 12 h was assessed by calculating sensitivity, specificity and the 
AuROC. Optimal cut-off levels were obtained by visual inspection of the AuROCs, 
giving equal weight to sensitivity and specificity. 
 
STUDY III 
Design and study population 
In Study III we included 327 patients registered in the PEAK, PROTIVA and 
EXCRETe databases between February 2007 and May 2010. AKI was defined as a rise 
in plasma creatinine of ≥ 50% relative to baseline. Patients were allocated to four 
different categories according to the presence of AKI and/or sepsis during the first 
week in the ICU: Category A, neither sepsis nor AKI (n = 151); Category B, sepsis 
without AKI (n = 80); Category C, AKI without sepsis (n = 24) and Category D, sepsis 
and AKI (n = 72). Our intention was to investigate the impact of the conditions AKI 
and sepsis on cystatin C levels in plasma. Patients may go in and out of these 
conditions during the ICU course. Furthermore, AKI and sepsis might not occur 
simultaneously in individual patients.  To account for this, we only included variables 
on days when the predefined criteria for each category were satisfied. For patients in 
category D, for instance, we excluded recordings obtained on days when AKI and 
sepsis criteria were not satisfied on the same day. Changes in creatinine, cystatin C, 
CRP and body weight were compared between septic and non-septic patients over the 
study period of seven days. Cystatin C was correlated to CRP on each day. The 
performance of cystatin C on admission to predict sustained AKI (> 3 d), worsening 
AKI (increase in RIFLE stage or RRT initiation) or death within seven days was 
assessed separately in septic and non-septic patients. 
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Statistical analysis 
Changes in creatinine, cystatin C, CRP and body weight over time were analysed using 
repeated measures analysis of variance (ANOVA) after logarithmic transformation 
(base 10). For comparison of changes over time between categories, an interaction 
variable (between category and time) was introduced in the ANOVA model. The 
relationship between CRP and cystatin C was measured by Spearman’s rank 
correlation. Diagnostic characteristics of cystatin C were assessed by ROC analysis. 
AuROCs were compared using the χ2-test. 
 
STUDY IV 
Design and study population 
A total of 782 urine samples were obtained from 83 patients and included in the PEAK 
database between August 2007 and April 2009. All samples were analysed for 
HNL/NGAL using the RIA method in a first step. Urine samples with a RIA-measured 
HNL/NGAL concentration ≥ 50 µg/l were selected for further analysis by Western 
blotting and two different ELISAs (ELISA-1 and ELISA-2). This cut-off point was 
chosen due to limitations in the sensitivity of the Western blot procedure. The antibody 
configurations of the ELISAs were as follows: in both assays the microtiter plates were 
coated with the monoclonal antibody clone 763. The detecting antibodies in ELISA-1 
and ELISA-2 were the monoclonal antibody clones 764 and 765, respectively.  
 
The Western blot patterns were evaluated in two ways. By scanning of the 
electropherograms, relative relations between monomeric and dimeric HNL/NGAL 
were constructed (monomer/dimer ratio). By visual inspection of the blot patterns, 
urine samples were classified according to the presence of monomeric and/or dimeric 
HNL/NGAL into (Figure 4): mainly monomeric HNL/NGAL (Class 1), monomeric 
and dimeric HNL/NGAL (Class 2) or mainly dimeric HNL/NGAL (Class 3).  
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Figure 4. Selection of urine samples and classification according to urine sample results. 
 
The ability of ELISA-1 and ELISA-2 to detect monomeric and dimeric HNL/NGAL 
was investigated by testing the association with the monomer/dimer ratio and by 
comparing the ELISA-1 and ELISA-2 concentrations between Classes 1–3. Finally, we 
identified patients with AKI as defined by a ≥ 50% increase in plasma creatinine from 
baseline or as an absolute rise in plasma creatinine of ≥ 26.4 µmol/l within 48 h 
according to the RIFLE/AKIN criteria. HNL/NGAL was quantified by ELISA-1 and 
ELISA-2 on the urine samples obtained from 24 h before (AKI day -1) until 48 h after 
(AKI day 2) the time-point when AKI was first diagnosed (AKI day zero). 
 
Statistical analysis 
The association between the monomer/dimer ratio and HNL/NGAL concentrations 
measured by ELISA-1 and ELISA-2, respectively, were investigated using quantile 
regression. We considered the 25th, 50th (median) and 75th percentile. We also applied 
quantile regression for comparison of HNL/NGAL values between categories, using 
Classes 1, 2 and 3 as dummy variables in the regression model. The Wald test was used 
to compare the coefficients in the model. The median change over time for the ELISA-
1 and ELISA-2 results was also tested by quantile regression using AKI day as the 
repeated-measures variable. Continuous variables were introduced in the statistical 
analyses after logarithmic transformation (base 10). Potential intra-individual 
dependence was taken into account in the regression models. Standard errors for the 
regression coefficients were obtained by generating 500 cluster-bootstrap samples, in 
which the individual was the re-sampling unit.
782 urine samples 
(in 83 patients) 
RIA analysis 
138 urine samples  
(in 48 patients) with 
HNL/NGAL ! 50 µg/l 
Western blot analysis 
132 urine samples 
(in 44 patients) 
Classification 
121 urine samples with      
HNL/NGAL ! 50 µg/l and 523 
urine samples with HNL/
NGAL < 50 µg/l  excluded 
6 urine sample without 
monomeric or dimeric       
HNL/NGAL excluded 
Class 1 
Mainly monomeric   
HNL/NGAL 
(49 samples in 22 pat) 
Class 3 
Mainly dimeric   
HNL/NGAL 
(20 samples in 12 pat) 
Class 2 
Monomeric & Dimeric   
HNL/NGAL 
(63 samples in 31 pat) 
135 urine samples 
(in 47 patients) 
Monomer/Dimer ratio 
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RESULTS 
STUDY I 
The AKI cohort 
Figure 5 shows the survival curves for AKI patients divided according to cystatin C 
quartiles and RIFLE stages at inclusion. The hazard ratios describing the association 
between quartiles of cystatin C and mortality were not significant after adjusting for 
age, ICU diagnosis and RIFLE stage in the Cox regression model. However, Figure 5 
indicates that cystatin C above the median (> 2.35 mg/l) was associated with higher 
long-term mortality.  
 
Figure 5. Survival curves of the AKI cohort by cystatin C (A) and RIFLE (B) level.   
 
In fact, when we compared cystatin C above and below the median during the second 
year onwards, hazard ratios were significant even after adjusting for RIFLE stage and 
APACHE II score (Table 5).  
 
Table 5. Relative risk of all-cause mortality in AKI patients 
Cystin C level (mg/l) HRa HRb 
Follow-up until day 365   
≤ 2.35 1.0 (ref) 1.0 (ref) 
> 2.35 1.62 (1.10–2.38) 1.46 (0.99–2.16) 
Follow-up from day 366 and onwards   
≤ 2.35 1.0 (ref) 1.0 (ref) 
> 2.35 5.01 (1.31–19.21) 5.29 (1.37–20.39) 
Hazard ratios (HRs) presented with 95% confidence intervals 
aAdjusted for age, ICU diagnosis. bAdjusted for age, ICU diagnosis, RIFLE and APACHE II score. 
!! A B 
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The non-AKI cohort 
In Figure 6 we show the survival curves of the non-AKI cohort stratified into quartiles 
based on cystatin C on ICU admission. Note that the highest quartile (Q4) was further 
divided into two groups (Q4:1 and Q4:2).  
 
 
Figure 6. Survival curves of the non-AKI cohort by cystatin C level.   
 
The point estimates for the relative risk of death increased with the cystatin C level and 
reached significance in the highest quartile (Q4). Higher point estimates were seen in 
the highest quartile after exclusion of 124 patients with potential AKI or when the 
analysis was restricted to patients under the age of 55 (Table 6). 
 
Table 6. Relative risk of all-cause mortality in non-AKI patients 
Cystatin C level (mg/l) HRa HRb HRc 
≤ 0.70 (Q1) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
0.71–0.91 (Q2) 1.78 (0.66–4.77) 1.81 (0.61–5.38) 1.39 (0.37–5.28) 
0.92–1.40 (Q3) 2.22 (0.86–5.75) 3.01 (1.06–8.53) 1.20 (0.28–5.04) 
1.41–1.78 (Q4:1) 3.81 (1.45–10.05) 5.53 (1.80–16.99) 6.15 (1.58–24.01) 
> 1.78 (Q4:2) 5.74 (2.20–14.96) 5.95 (1.83–19.36) 12.60 (3.25–48.87) 
Hazard ratios (HR) presented with 95% confidence intervals. Q, quartile. 
aAdjusted for age, ICU diagnosis. 
bAdjusted for age, ICU diagnosis and restricted to the 438 patients without potential AKI. 
cAdjusted for age, ICU diagnosis and restricted to the 325 patients under the age of 55. 
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STUDY II 
Biomarker levels in non-AKI patients 
The three groups were equally distributed regarding APACHE II score. Length of stay 
in the ICU increased with sepsis severity. Peak creatinine levels and maximum changes 
in creatinine relative to baseline did not differ significantly between the three groups. 
CRP, PCT and MPO levels, reflecting the degree of systemic inflammatory response 
and neutrophil activation, increased with sepsis severity (Table 7). Peak levels of 
plasma HNL/NGAL increased with sepsis severity and were elevated in 22 of the 27 
patients. Urinary HNL/NGAL levels also increased with sepsis severity but only four 
patients had peak urinary HNL/NGAL above the upper reference limit. Furthermore, a 
gradual increase in plasma and urinary cystatin C as well as urinary α1-microglobulin 
was observed. 
 
Table 7. Clinical characteristics and peak biomarker levels in the plasma and urine of patients 
without AKI 
 SIRS 
(n = 10) 
Severe sepsis 
(n = 10) 
Septic shock 
(n = 7) 
Age, yrs (IQR) 40 (30) 57 (11) 40 (46) 
Male gender, n (%) 6 (60) 8 (80) 4 (57) 
APACHE II score (IQR) 15 (15) 15 (6) 17 (6) 
ICU length of stay, days (IQR) 3.0 (2.0) 4.5 (2.0)a 10 (9.0)a, b 
True baseline creatinine available, n (%) 6 (60) 7 (70) 5 (71) 
Peak biomarker levels in plasma    
HNL/NGAL (ng/ml) 111 (67.8) 116 (27.6) 134 (72.7)b 
MPO (ng/ml) 108 (34.0) 198 (115)a 216 (502)a 
PCT (ng/ml) 0.54 (1.3) 1.4 (2.8) 2.8 (10.3)a 
CRP (mg/l) 112 (126) 251 (120)a 185 (137)a 
Cystatin C (mg/l) 0.8 (0.3) 1.0 (0.5) 1.4 (0.4)a 
Creatinine (µmol/l) 93.5 (29.0) 84.5 (21.0) 94.0 (52.0) 
Creatinine change relative to baseline (%) 12.9 (27.6) 2.1 (28.4) 22.7 (18.7) 
Peak biomarker levels in urine    
HNL/NGAL (ng/mg creatinine) 24.4 (34.4) 47.7 (29.1) 63.5 (133)a 
α1-microglobulin (mg/g creatinine) 96.6 (78.1) 138 (111) 159 (155) 
Cystatin C (mg/g creatinine) 0.35 (0.22) 0.86 (1.86)a 1.73 (7.31)a 
Values are expressed as the median (interquartile range [IQR]) or as n (%). SIRS, systemic 
inflammatory response syndrome; AKI, acute kidney injury. 
a p < 0.05 compared with SIRS. 
b p < 0.05 compared with severe sepsis. 
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Biomarker levels in AKI and non-AKI patients with septic shock 
CRP, PCT and MPO levels did not differ significantly between septic shock patients 
with and without AKI, indicating that the sepsis-induced inflammatory response was 
comparable between these two groups. Additionally, there was no significant difference 
in peak plasma HNL/NGAL levels between septic shock patients with and without 
AKI. Of the three potential markers of acute tubular injury, only levels of HNL/NGAL 
in urine were significantly higher in the AKI cohort. Urinary HNL/NGAL was a good 
predictor of AKI occurring within 12 h. In plasma, HNL/NGAL performed less well as 
an AKI predictor (Table 8). 
 
Table 8. Diagnostic characteristics of HNL/NGAL in plasma (p) and urine (u) for predicting AKI 
within 12 h in patients with septic shock. 
Variables Cut-off value AuROC Sensitivity Specificity 
pHNL/NGAL > 120 µg/l 0.67 (0.39–0.94) 0.83 (0.36–1.0) 0.50 (0.12–0.88) 
uHNL/NGAL > 68 ng/mg creatinine 0.86 (0.68–1.0) 0.71 (0.29–0.96) 1.0 (0.54–1.0) 
 
STUDY III 
Non-AKI patients with and without sepsis 
Characteristics of non-AKI patients with and without sepsis are compared in Table 9.  
 
Table 9. Characteristics of non-AKI patients with and without sepsis. 
 
No sepsis 
(n  = 151) 
Sepsis 
(n = 80) 
p value 
Male sex, n (%) 115 (76) 64 (80) 0.5 
Age (years) 41 (31) 41 (33) 1.0 
APACHE II score 13 (8) 16 (9) 0.0004 
True baseline creatinine available, n (%) 116 (77) 59 (74) 0.6  
Admission creatinine, µmol/l 79 (26) 83 (29) 0.04 
Admission cystatin C, mg/l 0.72 (0.23) 0.80 (0.47) 0.04 
Admission body weight, kg 78 (20) 78 (28)  0.7 
Corticosteroid treatment, n (%) 12 (8) 18 (23) 0.002 
High dose steroids*, n (%) 6 (4.0) 3 (3.8) 1.0 
Outcomes    
ICU length of stay, days 2.4 (1.9) 6 (5.9) 0.0001 
ICU mortality, n (%) 4 (2.6) 3 (3.8) 0.7 
30-day mortality, n (%) 6 (4.0) 6 (7.5) 0.3 
Values are expressed as the median (IQR) or as n (%).  
*Daily dose of > 300 mg hydrocortisone or equivalent. 
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Septic patients had higher APACHE II scores, longer ICU lengths of stay and were 
more often treated with corticosteroids, at least in low doses. Cystatin C and creatinine 
concentrations on admission were slightly higher in the septic group.  
 
Mean changes in cystatin C, creatinine and body weight over the first week in the ICU 
are displayed in Figure 7. Cystatin C increased and creatinine decreased significantly in 
septic (p = 0.0001) and non-septic patients (p < 0.0001) during the study period. The 
observed changes did not differ significantly between patients with and without sepsis 
(p = 0.59 for cystatin C and p = 0.78 for creatinine). Significant variations in body 
weight were only seen in the septic category and reached a 0.8% increase on the 
average by day 3. 
 
 
 
Figure 7. Change (mean ± SEM) in cystatin C (closed circles), creatinine (open circles) and body weight 
(open squares) relative to admission values: (A) non-AKI patients without sepsis; (B) non-AKI patients 
with sepsis. 
 
AKI patients with and without sepsis 
Characteristics of the AKI patients with and without sepsis are outlined in Table 10. 
Patients with septic AKI were older and stayed longer in the ICU than non-septic 
patients. The proportion of patients treated with RRT and corticosteroids was higher in 
the septic cohort. 
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Table 10. Characteristics of AKI patients with and without sepsis  
 
No sepsis 
(n = 24) 
Sepsis 
(n = 72) 
p value 
Male sex, n (%) 17 (71) 51 (71) 1.0 
Age (years) 55 (33) 64 (18) 0.08 
APACHE II score 18 (16) 22 (9) 0.2 
True baseline creatinine available, n (%) 12 (50) 39 (54) 0.7  
Admission creatinine, µmol/l 115 (53) 121 (83) 0.9 
Admission cystatin C, mg/l 1.21 (0.58) 1.36 (0.82) 0.2 
Admission body weight, kg 87 (27) 80 (28) 0.9 
Corticosteroid treatment, n (%) 4 (17) 28 (39) 0.08 
High dose steroids*, n (%) 1 (4.2) 9 (12.5) 0.4 
Outcomes    
RRT, n (%) 4 (17) 27 (38) 0.08 
ICU length of stay, days 3.5 (2.5) 10 (10) 0.0001 
ICU mortality, n (%) 3 (12.5) 9 (12.5) 1.0 
30-day mortality, n (%) 5 (21) 15 (21) 1.0 
Values are expressed as the median (IQR) or as n (%). 
*Daily dose of > 300 mg hydrocortisone or equivalent. 
 
Cystatin C gradually increased (p < 0.0001) during the first week in the septic AKI 
patients. By day 7, cystatin C levels had almost doubled on average (Figure 8). During 
the same time frame, creatinine did not change significantly (p = 0.86). The number of 
patients in the non-septic cohort was low and cystatin C results were only available 
during the first five days. During this period, cystatin C-changes did not differ 
significantly between septic and non-septic AKI patients (p = 0.13). Body weight 
changed significantly in both the septic (p = 0.0001) and non-septic patients (p = 0.02). 
 
 
Figure 8. Change (mean ± SEM) in cystatin C (closed circles), creatinine (open circles) and body weight 
(open squares) relative to admission values: (A) AKI patients without sepsis; (B) AKI patients with 
sepsis. 
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Inflammatory response in septic and non-septic patients 
In study III we assumed that the sepsis-induced systemic inflammation is more severe 
than systemic inflammation induced by other causes (e.g. trauma). To investigate this, 
we used CRP as an indicator of systemic inflammation for comparisons between septic 
and non-septic patients. On ICU admission, mean CRP levels were more than 4-fold 
higher in septic patients than in non-septic patients (p < 0.0001). CRP decreased in 
septic patients and increased in non-septic patients during the study period. Still, CRP 
levels remained significantly higher in septic patients during the first five days (Figure 
9). Furthermore, we found no significant correlation between CRP and cystatin C on 
any of the seven days. 
 
 
Figure 9. CRP levels (mean ± SEM) in septic (closed circles) and non-septic (open circles) patients. 
 
Impact of sepsis on cystatin C as a predictor of adverse events 
Sixty-seven patients with and 262 patients without sepsis on ICU admission had 
existing admission values of cystatin C. ROC curves for cystatin C as a predictor of 
sustained AKI, worsening AKI or death are shown in Figure 10. Cystatin C predicted 
the composite outcome in non-septic patients with an AuROC of 0.78 (95% CI, 0.70–
0.85). For septic patients, the corresponding AuROC was 0.80 (95% CI, 0.68–0.91). No 
significant difference between the two AuROCs was found (p = 0.76). 
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Figure 10. Receiver operating characteristics curves for cystatin C on ICU admission as a predictor of 
worsening AKI, sustained AKI or mortality within 7 days in septic (closed circles) and non-septic (open 
circles) patients. 
 
STUDY IV 
Association between HNL/NGAL levels and the monomer/dimer ratio 
Figure 11A-C shows the association between the relative amount of monomeric 
HNL/NGAL (monomer/dimer ratio) and HNL/NGAL quantified by the RIA, ELISA-1 
and ELISA-2 across the 25th, 50th (median) and 75th percentiles. HNL/NGAL quantified 
by the RIA and ELISA-1 increased with an increasing monomer/dimer ratio, whereas 
ELISA-2 results decreased with an increasing monomer/dimer ratio. The relationships 
were, however, only significant for the 50th and 75th percentiles. The ELISA-1/ELISA-
2 ratio showed a stronger association with the relative amount of monomeric 
HNL/NGAL which was significant across all three percentiles (Figure 11D).  
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Figure 11. Scatter plots showing the association between the monomer/dimer ratio and HNL/NGAL 
measured by RIA (A), ELISA-1 (B), ELISA-2 (C) and the ELISA-1/ELISA-2 ratio (D), respectively. 
Superimposed on the plots are the fitted 25th, 50th (median) and 75th percentile regression lines.  
 
Assay levels in samples with monomeric and/or dimeric HNL/NGAL 
HNL/NGAL levels quantified by the RIA, ELISA-1, ELISA-2 and the ELISA-
1/ELISA-2 ratio in samples visually classified as containing monomeric and/or dimeric 
HNL/NGAL are displayed in Figure 12 and summarized in Table 11. The median 
ELISA-1 concentration was significantly higher in samples containing mainly 
monomeric (Class 1) as compared to mainly dimeric (Class 3) HNL/NGAL. The 
opposite was true for ELISA-2. Finally, the median ELISA-1/ELISA-2 ratio was 
almost 240 times higher in Class 1 than Class 3 with the category containing both 
monomeric and dimeric HNL/NGAL as an intermediate.   
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Figure 12. HNL/NGAL levels quantified by by RIA (A), ELISA-1 (B), ELISA-2 (C) and the ratio 
between ELISA-1 and ELISA-2 (D) in urine samples classified as containing mainly monomeric 
HNL/NGAL (Monomer, Class 1), monomeric and dimeric HNL/NGAL (Monomer + Dimer, Class 2) or 
mainly dimeric HNL/NGAL (Dimer, Class 3).   
 
 
Table 11. Median HNL/NGAL levels measured by RIA, ELISA-1, ELISA-2 and the ELISA-1/ELISA-2 ratio 
in the different Western blot classes 
 Class 1 
(Monomer) 
Class 2 
(Monomer+Dimer) 
Class 3 
(Dimer) 
Overall  
p value† 
Median RIA, µg/l (IQR)  169.6 (606.88) 143 (231.7)b 63.78 (56.38) < 0.001 
Median ELISA-1, µg/l (IQR)  144.99 (388.44)b 118.07 (183.82)b 45.4 (64.49) 0.0128 
Median ELISA-2, µg/l (IQR) 0.1 (0)a, b 0.704 (4.01)b 10.37 (18.31) < 0.001 
Median ELISA-1/ELISA-2 ratio 
(IQR) 
959.82 (4217)a, b 67.55 (1002)b 4.127 (6.359) < 0.001 
†p values refer to the overall comparison of medians between Classes 1–3 using quantile regression and Wald 
test statistics, accounting for intra-individual dependence. 
ap < 0.05 compared with Class 2, bp < 0.05 compared with Class 3. 
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Panel of HNL/NGAL assays during AKI development 
Figure 13A displays the kinetics of HNL/NGAL, quantified by the ELISA-1 as well as 
the ELISA-2, in 32 AKI patients, of which 23 (78%) had sepsis, during the time frame 
of 24 h before and up to 48 h after the AKI diagnosis. In Figure 13B, the ELISA-
1/ELISA-2 ratios during the same time frame is shown.  
 
 
Figure 13. Median HNL/NGAL levels quantified by the ELISA-1 (A, closed circles) and ELISA-2 (A, 
open circles) and the median ELISA-1/ELISA-2 ratios (B, hollow diamonds) during the time frame from 
24 h before AKI (AKI day -1) and up to 48 h after the AKI diagnosis (AKI day 2). 
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DISCUSSION 
METHODOLOGICAL CONSIDERATIONS 
Study design 
The information about relevant exposures and outcomes, such as sepsis and AKI, was 
assessed prospectively in the databases generating the study populations in Studies I–
IV. Cohort studies are preferred when the outcome of interest is frequent. Conversely, 
when a rare outcome is expected, a case-control design is preferable.138 As stated 
above, AKI is a frequent outcome in the ICU. However, 20–40% of these patients 
already have AKI (according to RIFLE) on ICU admission.20, 139, 140 Since the main 
purpose of the PEAK database was to study biomarkers for AKI prediction, we only 
included patients with apparently normal renal function (GFR > 60 ml/min/1.73m2) on 
admission. Therefore, the frequency of AKI is lower in the PEAK database than 
expected in the general ICU population. To investigate the performance of HNL/NGAL 
in predicting future AKI (Study II), we used a nested case-control design. The 
predictive value for cystatin C was, on the other hand, evaluated using a cohort design 
in Study III. This was possible because sustained AKI (> 3 d) was part of the composite 
outcome and patients were therefore allowed to have AKI on admission. 
  
Generalizability 
The aim of many studies is to make an inference from the underlying source population 
from which the study sample is drawn. Since Studies I–IV are all single-centre studies, 
our findings may not be applicable to other ICUs treating a different case-mix. 
Generalizability is further reduced by our eligibility criteria. Studies II and IV exclude 
patients with renal dysfunction on admission. Study III included patients from three 
databases, consisting of different sub-populations, with overrepresentation of trauma 
patients from the PROTIVA database. Trauma patients are generally younger and have 
less frequent co-morbid conditions than the general ICU population. Study I is more 
representative since all consecutive patients were included in the AKI and non-AKI 
cohorts. In Study IV we only included urine samples with an HNL/NGAL 
concentration above 50 µg/l. Therefore, we cannot be sure that our assays effectively 
distinguish monomeric from dimeric HNL/NGAL at lower concentrations. 
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Misclassification 
Misclassification of AKI 
To investigate the performance of HNL/NGAL in predicting acute kindney injury, we 
used the RIFLE and/or AKIN classification as the reference method. This is 
problematic for two reasons. First, changes (absolute or relative) in plasma creatinine or 
urine output are markers of kidney function (i.e. GFR) rather than markers of renal cell 
damage. Increased creatinine levels and/or decreased urine output can be a 
physiological response to hypovolaemia/hypotension without any signs of kidney 
injury. Patients in whom such responses occur will certainly be misclassified as having 
AKI. The opposite may also be true – damage to the kidney epithelium might go 
undetected by changes in creatinine and urine output. Second, the RIFLE/AKIN criteria 
are based on changes in creatinine from baseline. When baseline creatinine is unknown, 
which may often be the case, it is estimated by the MDRD formula using a GFR in the 
lower normal range (75 ml/min/1.73m2). This might overestimate baseline creatinine 
(and hence underestimate the relative creatinine change), especially in patients with 
habitually low creatinine levels due to reduced muscle mass, with the risk of 
misclassifying AKI patients into the non-AKI cohort. Conversely, in patients with 
unknown CKD, the baseline will be underestimated and these patients will be 
misclassified as having AKI.141  
 
Misclassification cannot be ruled out in Study II where more non-AKI patients (29–
40%) had missing baseline values as compared to the AKI patients (22%). In Study III 
a true baseline was only present in 50% of AKI patients and in as many as 70% of non-
AKI patients. Our comparison between patients with and without sepsis was, however, 
restricted to the AKI and non-AKI cohorts, respectively. Fortunately, the same 
proportion of available baseline values was present in septic and non-septic patients. 
 
Misclassification of sepsis 
The SIRS criteria describe the physiological response to non-infectious triggers such as 
trauma, pancreatitis and immunological reactions. Unfortunately, the criteria are overly 
sensitive and hence describe a heterogeneous group of disorders with different causes 
and outcomes. When SIRS arises in response to a suspected infection, sepsis is said to 
be present. Often, an infection is difficult to confirm microbiologically and patients 
Johan Mårtensson   
 
 46 
with ‘pure’ SIRS might be misclassified as having sepsis. The definitions of severe 
sepsis and septic shock are also non-specific, especially when they are used to describe 
different stages of severity. In fact, patients with septic shock do not always satisfy the 
criteria for severe sepsis. One of our aims in Study II was to investigate biomarker 
levels in patients with SIRS, severe sepsis and septic shock. Here, we assumed that the 
systemic inflammatory response was least severe in the SIRS group and most severe in 
patients with septic shock. This might not always be the case: a patient with SIRS can 
be in circulatory shock with severe multiorgan failure but without any signs of an 
infection, whereas a patient classified as having septic shock may simply have a slow 
infusion of a vasopressor without other signs of organ failure. Luckily, our biomarkers 
of inflammation (CRP, MPO) and infection (PCT) supported an increasing 
inflammatory response going from SIRS to septic shock. 
 
Confounding 
Confounders are factors that are associated with both the putative cause and its effect. 
In contrast, intermediate factors in the causal pathway between exposure and outcome 
are not confounders. Confounders can be dealt with in several ways: in the study design 
by randomization, restriction and matching, and in the data analysis by stratification or 
by adjusting for the confounder in a regression analysis.  
 
Study I 
Multivariable regression was used in Study I to demonstrate the confounding effect of 
AKI severity (RIFLE stage) on the association between cystatin C levels and mortality 
in the AKI cohort. Illness severity (APACHE II), ICU diagnosis and age were also 
considered potential confounders and were therefore adjusted for in the analysis. 
 
Studies II and III 
Both restriction and stratification were used in Studies II and III to investigate the 
impact of sepsis on biomarker levels in plasma and urine. In Study II we stratified 
patients according to sepsis severity and restricted the analysis to non-AKI patients in 
order to remove the effect of AKI and demonstrate the impact of sepsis on biomarker 
levels. In the same study we also restricted our ROC analysis to patients with septic 
shock in order to assess the performance of HNL/NGAL in predicting AKI. In Study III 
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we restricted patients to AKI and non-AKI cases to investigate the impact of sepsis on 
cystatin C in these separate groups. In the next step we stratified patients according to 
the presence or absence of sepsis and compared the predictive performance of cystatin 
C between these two strata.  
 
Random errors 
The Latin word ‘error’ means ‘to wander’ and its use in statistics refer to fluctuations of 
measurements around the true value. A systematic error tends to shift all measurements 
away from the true value in a predictable and systematic way. An example is when an 
instrument is not correctly calibrated. In contrast to systematic errors, random errors are 
inherently unpredictable and will always be present when a biological quantity is being 
measured. The precision of a measurement is largely affected by random errors and can 
be reflected by the p value and the confidence interval. In this thesis we have compared 
biomarker levels between different pre-defined groups of ICU patients, drawn from a 
source population – mainly AKI and non-AKI patients with and without sepsis. We 
found that the median biomarker levels were not identical among these groups. Does 
this reflect the likelihood that a true difference exists between these groups in the 
source population or was it just a coincidence of random sampling? Since we do not 
have data on the entire source population, we can only say whether a random error is 
probable or not. The p value is a probability, which answers the question: If the 
populations really have the same median biomarker levels, what is the probability that 
random sampling would lead to a difference between sample medians as large (or 
larger) than we observed? In other words, if the p value is 0.01, for example, random 
sampling from identical populations would lead to a difference smaller than we 
observed in 99% of experiments and larger than we observed in 1% of experiments. 
 
If we conclude that there is a difference between biomarker levels among our groups 
when, in fact, no difference exists, a type I error would occur. The probability of 
making a type I error is usually allowed to be less than 5% and is referred to as the level 
of the test. 
 
If we, instead, conclude that there is no difference between our groups, a difference 
may still exist, but our sample is not large enough to detect it (type II error). This may 
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have happened in Study II when we failed do demonstrate significant differences in 
biomarker levels between some of the groups.  
 
INTERPRETATION OF FINDINGS 
So far, the diagnosis of AKI has relied upon markers of GFR (kidney function) instead 
of renal cell damage. There are reasons to believe that future treatment of AKI will 
depend on our ability to detect AKI as early as possible after the kidney insult, even 
before the functional impairment is obvious. To date, a number of potential markers of 
renal cell damage have emerged. However, their ability to detect AKI and monitor the 
course of the disease appears to be hampered by the confounding effect of other co-
existing conditions. An ideal AKI biomarker should be:142 (a) rapid and easy to 
measure in blood or urine; (b) sensitive in order to establish an early diagnosis while 
damage is still potentially reversible; (c) specific to AKI; (d) associated with a known 
mechanism; (e) should increase in proportion to the degree of damage; and (f) be able 
to monitor the course of AKI.  
 
In addition, it should be pointed out that robust functional measurements of GFR will 
continue to be important, e.g. for drug dosing. In this thesis, the impact of sepsis on 
levels of cystatin C and HNL/NGAL in critically ill patients with and without AKI is 
investigated.  An improved platform to detect different sources of HNL/NGAL in urine 
is also suggested and may be a useful tool as a monitor of pathophysiological changes 
during AKI development. 
 
Cystatin C 
In contrast to creatinine, cystatin C satisfies many features of an ideal filtration marker. 
In some studies cystatin C outperformed creatinine in detecting minor reductions in 
GFR.143, 144 Furthermore, Shlipak et al. found that cystatin C predicted mortality in 
outpatients with apparently normal kidney function.145 The practical use of cystatin C 
as a marker of kidney function and/or mortality in general ICU patients has not, 
however, been fully investigated.  
 
The aim of Study I was to investigate whether cystatin C had the ability to predict long-
term mortality, irrespective of the presence of AKI, in a general ICU population. In this 
  Discussion 
 
 49 
study we found that plasma cystatin C was independently associated with long-term 
mortality. We reached this conclusion by analysing our data in several steps. First, we 
observed a gradual increase in mortality among cystatin C quartiles in our AKI cohort.  
Significance was not reached, however, when we adjusted for AKI severity (RIFLE 
stage). This was expected since cystatin C mirrors reduced GFR, which is a feature of 
AKI, and because there is a well-known association between AKI severity and 
mortality.146 Second, when we compared cystatin C above and below the median (2.35 
mg/l) from the 2nd year and onwards, a strong association with mortality was found, 
independently of AKI severity. The corresponding association could not be 
demonstrated during the first year. This suggests that AKI has an early impact on 
mortality and that cystatin C carries additional information when this early risk has 
resolved. Third, when we investigated our non-AKI cohort we found an association 
between ICU admission levels of cystatin C and mortality. This association was further 
strengthened after removing patients with ‘potential’ AKI.  
 
Our results raise the question: Do patients enter the ICU with differing baseline risks, 
dependent on or independently of GFR, and does cystatin C measure this risk? In the 
above-mentioned study by Shlipak et al., cystatin C predicted subsequent development 
of CKD in patients with a normal GFR (estimated by creatinine).145 Moreover, Van 
Biesen et al. found that even mild reductions in kidney function in apparently healthy 
individuals are associated with increased mortality.147 Perhaps CKD is the intermediate 
link between cystatin C and late mortality in our study. It should be possible to answer 
this question if ICU patients with different cystatin C values were followed a long time 
after ICU discharge with GFR measurements, using established reference methods (e.g. 
inulin or iohexol clearance).  
 
An alternative explanation to our observed association is that non-renal factors affect 
the levels of cystatin C in plasma. Others have found a correlation between cystatin C 
levels and CRP80, 81 as well as elevated levels in patients with HIV148 and leukemia.149 
This may indicate a possible impact of inflammation on cystatin C. Cystatin C is a 
strong inhibitor of proteolytic enzymes, e.g. caspases. Since caspase-activity is up-
regulated in sepsis,37 we speculated that sepsis per se might trigger the increase in 
cystatin C. This was further investigated in Studies II and III. 
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In Study II we compared peak levels of plasma cystatin C between non-AKI patients 
with SIRS, severe sepsis and septic shock and found a gradual increase in peak levels 
with increasing sepsis severity. The additional analysis of several markers of 
inflammation (CRP, MPO, PCT) supported the view that the systemic inflammatory 
response increased with sepsis severity (Table 7). Furthermore, we compared cystatin C 
between septic shock patients with and without AKI. The inflammatory markers did not 
differ significantly between these two latter groups, but cystatin C was significantly 
higher in the AKI patients. Indeed, this study indicates an impact of sepsis on cystatin 
C levels and, as could be expected, that the levels increase further in AKI. However, 
the fact that septic patients also stayed longer in the ICU reflects that these patients 
were sicker and thus more extensively exposed to other known or unknown factors that 
may have a potential impact on the cystatin C levels. 
 
In fact, this was illustrated in Study III in which we explored the impact of the sepsis-
induced systemic inflammatory response on cystatin C alterations on each of the first 
seven days in the ICU. Interestingly, we found a daily increase in cystatin C in our ICU 
patients, even in those without AKI. But in contrast to what we had expected from the 
results in Study II, a similar increase was observed in both septic and non-septic 
patients. The assumption that sepsis per se does not affect cystatin C levels was further 
supported by our additional findings: (1) no correlation between cystatin C and CRP 
was found on any of the seven days and (2) the performance of cystatin C in predicting 
our composite outcome was similar in septic and non-septic patients. It is, however, 
possible that the systemic inflammatory response, irrespective of the presence of sepsis, 
was responsible for the increase in cystatin C. In fact, our non-septic cohorts mainly 
consisted of patients with SIRS. The fact that CRP levels were significantly higher in 
septic patients during the first five study days reflects that sepsis induced a more severe 
inflammatory response. Furthermore, Grubb et al. found no changes in cystatin C levels 
after surgically induced systemic inflammation.82  
 
Then what does this daily increase reflect? Is it a gradual decline in GFR? This is 
unlikely since creatinine gradually decreased during the same time frame. There are, 
however, several reasons for why creatinine does not accurately reflect early changes in 
GFR. Increased TBW due to massive volume expansion can dilute plasma 
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creatinine.150 This is not a plausible explanation for the observed changes in our study 
since only minor variations in body weight were observed, at least in the non-AKI 
patients. Any significant changes in TBW in these patients are therefore highly 
unlikely. A more plausible explanation could be decreased creatinine production, e.g. 
due to a gradual loss of muscle mass, which is a well-known phenomenon in ICU 
patients.  
 
It is also a well-known fact that corticosteroids induce the production of cystatin C, at 
least in high doses.67, 151 Furthermore, it appears that steroids affect cystatin C and 
creatinine in opposite directions.68 Theoretically, this could have some impact on the 
different changes seen in Study III. It is, however, unlikely that the low proportion of 
patients treated with high-dose steroids caused the divergent changes in creatinine and 
cystatin C over time. In the light of the drawbacks of creatinine, we cannot be sure that 
the rise in cystatin C actually reflected a true decrease in GFR. To finally answer this 
question, cystatin C and creatinine must be compared with proper GFR measurements 
(e.g. inulin or iohexol-clearance) over several ICU days and over a wide range of renal 
function. 
 
HNL/NGAL 
Several studies show that HNL/NGAL is able to predict AKI in a general ICU 
setting.139, 152-155 Common to these studies is the over-representation of sepsis among 
AKI patients. We hypothesized that sepsis will confound the interpretation of plasma 
HNL/NGAL in AKI since circulating neutrophils release their HNL/NGAL in response 
to bacterial infections.91, 92 The origin of urinary HNL/NGAL in AKI is not fully 
understood. Increased synthesis within the kidney parenchyma has been proposed, but 
elevated plasma levels may also contribute, and perhaps more so in sepsis, since 
HNL/NGAL is filtered from the blood.  
 
In Study II we investigated the impact of systemic inflammation and sepsis on the 
concentrations of HNL/NGAL in plasma and urine. In addition, we assessed the ability 
of HNL/NGAL to predict AKI in patients with septic shock. We found that plasma 
HNL/NGAL was elevated in most of our non-AKI patients with SIRS, severe sepsis 
and septic shock. Furthermore, plasma HNL/NGAL, as well as our markers of systemic 
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inflammation (CRP), severe bacterial infection (PCT) and neutrophil activation (MPO), 
gradually increased with sepsis severity. Based on these findings, it appears reasonable 
to assume that the activated neutrophils represent the main source of the increase in 
HNL/NGAL levels. However, other organs may also contribute to HNL/NGAL 
production and secretion into the circulation as a consequence of sepsis and multi-organ 
damage. Since HNL/NGAL is filtered in the glomeruli, we would expect plasma levels 
to increase further in septic patients with impaired kidney function. When we compared 
septic shock patients with and without AKI, however, we found no significant 
difference in peak levels of HNL/NGAL in plasma. The clinical implication of this was 
revealed when we found that plasma HNL/NGAL was unable to predict AKI within 12 
h in patients with septic shock.   
 
Similarly to HNL/NGAL in plasma, urine concentrations rose in a stepwise manner 
with increasing sepsis severity. However, the peak concentrations in urine remained 
below the upper reference limit in most patients without AKI. It could be argued that 
filtered plasma HNL/NGAL accounted to some extent for the rise in urine. 
Alternatively, decreased tubular uptake of filtered HNL/NGAL might play a role. 
Others have suggested that sepsis per se triggers albuminuria156 and that albumin 
competitively inhibits the megalin receptor-mediated re-uptake of HNL/NGAL and 
other LMWPs in the proximal tubule.85 Although we lack information about urinary 
albumin concentrations, our findings that all three urinary markers (HNL/NGAL, α1-
microglobulin and cystatin C) increased with sepsis severity support this view. 
Furthermore, it should be noted that three out of seven non-AKI patients with septic 
shock showed a more than 25% increase in creatinine. These patients may indeed have 
a mild kidney injury leading to an accumulation of urinary proteins. In contrast to 
HNL/NGAL in plasma, urinary levels were five-fold higher in AKI patients than in 
non-AKI patients. Besides, the performance in predicting AKI from urinary 
HNL/NGAL in septic shock patients was good with an AuROC of 0.86.  
 
It is important to emphasize that a polyclonal antibody-based RIA was used to quantify 
HNL/NGAL in Study II. Hence, it is likely that all molecular forms of HNL/NGAL 
(monomeric, dimeric and heterodimeric), if present, were detected in plasma and 
urine.157 It was recently shown in an in vitro study that kidney epithelial cells mainly 
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release monomeric HNL/NGAL, whereas neutrophils mainly secrete the dimeric 
form.113 Moreover, Cai et al. not only detected both molecular forms in the urine (using 
Western blot) from patients after cardiac surgery, but also noted that the relative 
relations between monomeric and dimeric HNL/NGAL varied over time.114  
 
The total concentration of urinary HNL/NGAL in AKI, measured by the RIA, probably 
represents a mixture of different molecular forms of HNL/NGAL with different cellular 
origins. Urinary monomeric HNL/NGAL levels increase either due to an induced 
synthesis in the tubular cells or as an effect of impaired reabsorption of the filtered load 
produced by extra-renal tissues. Furthermore, infiltration of neutrophils in the kidney 
has been observed in both animal models and in biopsy specimens from patients with 
AKI.41, 53 Dimeric HNL/NGAL in urine might emanate from these infiltrating 
neutrophils, but glomerular filtration of dimeric HNL/NGAL released from activated 
neutrophils in the circulation, e.g. in septic patients, may also contribute. 
 
In Study IV we used Western blotting to detect monomeric and dimeric HNL/NGAL, 
respectively, in the urine from critically ill patients. Based on the Western blot results, 
we examined the ability of two monoclonal ELISAs, with different epitope 
specificities, to distinguish between the monomeric and dimeric forms.  
 
When we compared the results from the assays with the Western blot patterns (Figure 
12) we made some interesting findings. First, the polyclonal RIA measured all three 
forms of HNL/NGAL as we expected (Figure 12A). Second, we found that the ELISA-
1 levels were dependent on the relative amount of monomeric HNL/NGAL. However, 
ELISA-1 was not monomer-specific since the assay also detected the dimeric form 
(Figure 12B). Third, ELISA-2 almost exclusively detected dimeric HNL/NGAL. In 
fact, levels were below the detection limit (< 0.1 µg/l) in 12 out of 20 urine samples 
with mainly the monomeric form. It must, however, be acknowledged that the absolute 
ELISA-2 levels were much lower than the ELISA-1 and the RIA levels in samples with 
mainly the dimeric form (Figure 12C). Hence, it appears that ELISA-2 only detects a 
fraction of the total amount of dimeric HNL/NGAL. A possible explanation for this 
might be that some of the specific epitopes which interact with the detecting antibody 
in ELISA-2 (clone 765) are partially ‘hidden’ when HNL/NGAL is present as a dimer.  
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Since the kidney epithelial cells mainly release the monomeric form of HNL/NGAL in 
response to cell damage, it would be of interest to ‘remove’ the dimeric signal in urine 
in order to study the state of the tubular epithelial cells. We achieved that by 
constructing the ELISA-1/ELISA-2 ratio, which amplified the monomeric signal and 
almost completely distinguished monomeric from dimeric HNL/NGAL (Figure 12D). 
We therefore concluded that the ELISA-1/ELISA-2 ratio could be used as a more 
specific measure of tubular epithelial damage than the ELISA-1 alone. 
 
The effect of amplifying the monomeric signal was highlighted when we studied the 
kinetics of HNL/NGAL, quantified by our two ELISAs, in patients with AKI. A weak 
but detectable dimeric signal was picked up 24 h prior to the AKI diagnosis and 
gradually decreased thereafter (Figure 13A). On the other hand, the concentrations 
measured with ELISA-1 did not change during the observed time frame. This may 
reflect the fact that ELISA-1 also measured the dimeric HNL/NGAL present in urine 
during the pre-AKI phase. The monomer-specific ELISA-1/ELISA-2 ratio significantly 
increased during AKI development (Figure 13B). This increase may represent an 
induced synthesis of monomeric HNL/NGAL from the tubular cells.  
 
Evidence from animal models suggests that neutrophils mediate tubular injury and play 
an important role in the development of AKI.40 It could be speculated that the 
monomeric and dimeric forms, respectively, reflect different pathophysiological events 
during the course of AKI. The dimeric signal that we detected prior to the AKI 
diagnosis might represent an involvement of neutrophils early on in the AKI initiation 
process. This is supported by several animal studies where depletion or inhibition of 
neutrophil accumulation in the kidney ameliorated AKI.158 However, results are 
conflicting and it is a fact that neutropenic patients are not protected against AKI. 
 
Based on the results in Sudies II and IV, we conclude that plasma HNL/NGAL should 
be used with caution as a marker of AKI in general ICU patients since sepsis alone 
increases plasma levels significantly. In contrast, urinary levels are less affected by 
sepsis and urinary HNL/NGAL is therefore a more robust AKI predictor. In addition, 
we suggest that, by using a combination of different anti-HNL/NGAL antibodies 
(ELISA-1/ELISA-2 ratio), it is possible to distinguish between the monomeric and 
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dimeric forms. This could make the diagnostic accuracy of an HNL/NGAL 
immunoassay in the urine of patients with suspected AKI much improved since the 
contribution of neutrophil-derived HNL/NGAL will be, at least partly, eliminated. The 
ELISA-2 assay may also shed light on the pathogenesis of AKI since the participation 
of neutrophils is likely in some patients, knowledge which may have a bearing on 
future treatment strategies. 
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CONCLUSIONS 
• Cystatin C on ICU admission predicts mortality in patients without kidney 
dysfunction measured by creatinine. Cystatin C predicts long-term mortality 
independently of AKI and illness severity in the ICU.  
 
• The sepsis-induced inflammatory response does not affect cystatin C levels in 
plasma.  
 
• HNL/NGAL in plasma is a non-specific predictor of AKI in patients with 
septic shock since septic shock per se increases plasma levels of HNL/NGAL. 
 
• Urinary HNL/NGAL predicts AKI in patients with septic shock. 
 
• A combination of monoclonal antibodies directed against different epitopes on 
the HNL/NGAL molecule can distinguish between monomeric and dimeric 
HNL/NGAL in urine. 
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